Protocol I8B -MC-ITRO (c)  
 
 
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog in Adults with 
Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion PRONTO-Pump-2 
 
[STUDY_ID_REMOVED] 
 Approval Date: 8- Oct-2019
 
 
 
 
I8B-MC-ITRO(c)Clinical Protocol Page 1
LY900014Protocol I8B-MC-ITRO (c)
A Prospective, Randomized, Double -Blind Comparison of 
LY900014 to Humalog in Adults with Ty pe 1 Diabetes Using 
Continuous Subcutaneous Insulin Infusion
PRONTO -Pump -2
2015 -005358 -36(EUDRA CTA )
Confidential Information
The information contained in this document is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copi[INVESTIGATOR_105304]900014 , unless such persons are bound by a confidentiality agreement with Eli Lilly and 
Company or its subsidiaries .  
Note to Regulatory Authorities :  This d ocument may contain protected personal data 
and/or commercially confidential information exempt from public disclosure. Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release. In 
the [LOCATION_002], this docume nt is subject to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries.
LY900014
Study I8B -MC-ITRO is a Phase 3, prospective, randomized, double -blind, outpatient, 
multi -national, multi -center, 2-treatment group parallel, active -controlled study conducted in 
patient s with type 1 diabetes currently using continuous subcutaneous insulin infusion.
Eli Lilly and Company
Indianapolis, Indiana [LOCATION_003] [ZIP_CODE]
Protocol Electronically Signed and Approved by [CONTACT_11007] 17 October 2018
Amendm ent (b) Electronically Signed and Approved by [CONTACT_11007] 21 June 2019
Amendm ent (c ) Electronically Signed and Approved by [CONTACT_443190]: 08-Oct-2019 GMT
I8B-MC-ITRO(c)Clinical Protocol Page [ADDRESS_563644] ivities....................................................................................................... 13
3. Intro duction ...................................................................................................................... 20
3.1. Study  Rati onale ............................................................................................................ 20
3.2. Background .................................................................................................................. 20
3.3. Benefit/Risk Assessment .............................................................................................. [ADDRESS_563645] ions.................................................................................................... 34
6.4. Screen Failures ............................................................................................................. 34
7. Treatments ........................................................................................................................ 35
7.1. Treatments Admi nistered ............................................................................................. 35
7.1.1. Packaging and Labelling ...................................................................................... 35
7.1.2. Insulin Pumps ...................................................................................................... 35
[IP_ADDRESS]. Personal Cont inuous Glucose Monitor Use in Study ....................................... 36
7.1.3. Medical Devices ................................................................................................... 36
7.2. Method of Treatment Assignment ................................................................................ 36
7.2.1. Selection and Timing o f Doses ............................................................................. 37
[IP_ADDRESS]. Target Gl ucose Val ues f or Ti tration of  Insulin Therapy .................................. 37
[IP_ADDRESS]. Pump Settings .................................................................................................37
[IP_ADDRESS]. Basal Rate Titration ........................................................................................ 37
[IP_ADDRESS]. Bolus Dose Ti tration....................................................................................... 38
[IP_ADDRESS]. Transit ioning o ff Study Prandial Insulin Therapy ............................................ 39
7.3. Blinding ....................................................................................................................... 39
I8B-MC-ITRO(c)Clinical Protocol Page 3
LY9000147.4. Dosage Modification .................................................................................................... 39
7.5. Preparati on/Handling/Storage/Accountabilit y............................................................... [ADDRESS_563646] to Follow -
up......................................................................................................... 44
9. Study  Assessments and Procedures ................................................................................... 45
9.1. Efficacy Assessments ................................................................................................... 45
9.1.1. Primary Efficacy  Assessments ............................................................................. 45
9.1.2. Secondary  Efficacy  Assessments .......................................................................... 45
9.1.3. Appropriateness of Assessments .......................................................................... 46
9.1.4. Study  Procedures .................................................................................................46
[IP_ADDRESS]. Use of Personal CGM or FGM ....................................................................... 46
[IP_ADDRESS]. Collect ion of Glucose Profiles ........................................................................ 46
[IP_ADDRESS]. Use of Study  Provi ded Bl ood Gl ucose Meter .................................................. 47
[IP_ADDRESS]. Infusio n Set Changes ...................................................................................... 47
[IP_ADDRESS]. Urine Ketone Testing ...................................................................................... 48
[IP_ADDRESS]. Blinded Continuous Glucose Monitoring Sessio ns.......................................... 48
[IP_ADDRESS]. Mixed Meal To lerance Test ............................................................................ 49
[IP_ADDRESS]. Diabetes Educati on and Nutri tional Counseling .............................................. 51
9.2. Adverse Events ............................................................................................................ 51
9.2.1. Serious Adverse Events ........................................................................................ 52
[IP_ADDRESS]. Suspected Unexpected Serious Adverse React ions.......................................... 53
9.2.2. Com plaint Handling ............................................................................................. 53
9.3. Treatment of Overdose .................................................................................................54
9.4. Safety........................................................................................................................... 54
9.4.1. Hypoglycemia ...................................................................................................... 54
9.4.2. Severe Hypoglycemia .......................................................................................... 55
9.4.3. Electrocardiograms .............................................................................................. 55
9.4.4. Vital Signs ........................................................................................................... 56
I8B-MC-ITRO(c)Clinical Protocol Page 4
LY9000149.4.5. Laborat ory Tests .................................................................................................. 56
9.4.6. Safety Moni toring ................................................................................................ 56
[IP_ADDRESS]. Hepati c Safet y Moni toring .............................................................................. [ADDRESS_563647] ical Considerat ions........................................................................ 60
10.3.2. Treatment Group Comparabilit y........................................................................... 62
[IP_ADDRESS]. Patient Disposi tion.......................................................................................... 62
[IP_ADDRESS]. Patient Characteri stics.................................................................................... 62
[IP_ADDRESS]. Concomitant Therapy ..................................................................................... 62
10.3.3. Efficacy Analyses ................................................................................................ 62
[IP_ADDRESS]. Primary Analyses ........................................................................................... 62
10.3.3 .1.1. Sensit ivity Analyses for Missing Data ....................................................... 63
[IP_ADDRESS]. Secondary  Analyses ........................................................................................ 64
[IP_ADDRESS]. Terti ary/Exploratory  Analyses ........................................................................ 64
10.3.4. Safety Analyses .................................................................................................... 65
10.3.5. Other Analyses ..................................................................................................... 66
[IP_ADDRESS]. Health Economics ........................................................................................... 66
10.3.5 .2. Subgroup Analyses ......................................................................................... 66
10.3.6. Interim Analyses .................................................................................................. 67
11. References ........................................................................................................................ 68
12. Appendices ....................................................................................................................... 69
I8B-MC-ITRO(c)Clinical Protocol Page [ADDRESS_563648] ion Schedule for Glucose Profiles ....................................................... 47
I8B-MC-ITRO(c)Clinical Protocol Page [ADDRESS_563649] of Figures
Figure Page
Figure ITRO.1. Illustrati on of  study  design for Clinical Protocol  I8B-MC-ITRO. ................... 26
I8B-MC-ITRO(c)Clinical Protocol Page [ADDRESS_563650] of A ppendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions........................................................................ 70
Appendix 2. Clinical Laboratory  Tests ............................................................................... 74
Appendix 3. Study  Governance Considerat ions.................................................................. 75
Appendix 4. Hepati c Moni toring Tests for Treatment -Emergent Abnormalit y.................... 79
Appendix 5. Classificat ion of Contraceptive Methods ........................................................ 80
Appendix 6. Protocol  Amendment I8B -MC-ITRO (c) Summary
A Prospective, Rando mized, Double -Blind Co mparison of LY900014 
to Humalog in Adult s with Type 1 Di abetes Using Continuous 
Subcutaneous Insulin Infusio n
PRONTO -Pump -
2......................................................................................... 81
I8B-MC-ITRO(c)Clinical Protocol Page 8
LY9000141.Synopsis
Title of Study:
A Prospective, Randomized, Double -Blind Comparison of LY900014 to Humalog in Adults with Type 1 Diabetes 
Using Co ntinuous Subcutaneous Insulin Infusion :  PRONTO -Pump-2.
Rationale: 
Rapid -acting insulins have been shown to have a more rapid onset of action compared with human insulin; however, 
the consensus is that they are not rapid enough to match carbohydrate absorption and many patients are unable to 
achieve optimal glycemic control.  
An ultra -rapid -acting prandial insulin with pharmacokinetic (PK) and pharmacodynamic (PD) profiles that 
demonstrate fast er absorption and onset of action, may better match carbohydrate absorption and lead to improved 
postprandial control.  The time action profile of a rapid -acting insulin could be enhanced through the addition of 
excipi[INVESTIGATOR_443175]/or enhance vascular permeability.  An 
ultra-rapid insulin would be useful in the treatment of type 1 diabetes (T1D) and type 2 diabetes (T2D) when 
delivered by [CONTACT_213428] (MDI s), by [CONTACT_443191] (CSII), and in the 
development of closed loop insulin delivery systems.  
The aim of this study is to demonstrate that an ultra -rapid formulation of insulin lispro, LY900014, is noninferior to 
Humalog on glycemic control as measured by [CONTACT_443192] 16 in HbA1c in patients with T1D 
using CSII when bolus doses are delivered in a double -blind manner immediately prior to each meal via an insulin 
pump.  
Objective(s)/Endpoints:
Objectives Endpoints
Primary Objective
1.To test the hypothesis that LY900014 is 
noninferio r to Humalog on glycemic 
control ([NIM =0.4% for HbA1c) in 
patients with T1D using CSII for [ADDRESS_563651] the hypothesis that LY900014 is 
superior to Humalog in controlling 1-hour 
postprandial glucose (PPG) 2.Difference between LY900014 and Humalog in 
the 1 -hour PPG (serum glucose measured 1 
hour after the start of the meal) from a MMTT 
at Week [ADDRESS_563652] the hypothesis that LY900014 is 
superior to Humalog in controlling 2-hour 
PPG 3.Difference between LY900014 and Humalog in 
the 2 -hour PPG (serum glucose measured 2 
hoursafter the start of the meal) from a MMTT 
at Week [ADDRESS_563653] the hypothesis that LY900014 is 
superior to Humalog on improving glycemic 
control (HbA1 c) 4.Difference between LY900014 and Humalog in 
change from baseline to Week 16 in HbA1c
I8B-MC-ITRO(c)Clinical Protocol Page [ADDRESS_563654] the hypothesis that LY900014 is 
superior to Humalog inthe duration of time 
glucose values within target range 70to 
180mg/dL (
3.9 to 10.0 mmol/L ), obtained 
from CGM us e during 24-hour period5.Duration (in minutes and percentage of time )
with glucose values between 7 0and 180 mg/dL 
(3.9 and 10.0 mmol/L), both inclusive, 
normalized to a 24- hour period, from each 
14-day  CGM session at Week [ADDRESS_563655] the hypothesis that LY900014 is 
superior to Humalog in the duration of time 
glucose values with in target range 70 to 
180mg/dL (3.9 to 10.0 mmol/L ), obtained 
from CGM us e during daytime6.Duration (in minutes and percentage of time )
with glucose values between 7 0and 180 mg/dL 
(3.9 and 10.0 mmol/L), both inclusive, 
normalized to daytime (0600 hours to 
midnight) , from each [ADDRESS_563656] to the rate of severe hypoglycemic 
events7.Rate (events/ patient /100 years) of severe 
hypoglycemic events from baseline through 
Week [ADDRESS_563657] to the rate and incidence of 
documented postmeal hypoglycemia 8.Rate (events/ patient /year) and incidence 
(percen tof patients with at least 1event) of 
documented post meal hypoglycemia within 
1and 2hoursafter the start of themeal from 
baseline through Week [ADDRESS_563658] to the rate and incidence of 
documented hypoglycemia9.Rate (events/ patient /year) and incidence 
(percent ageof patients with events) of 
documented hy poglycemic events from baseline 
through Week [ADDRESS_563659] to total, basal, and bolus insulin dose12.Change f rom baseline in bolus/total insulin dose 
ratio at Week [ADDRESS_563660] to the proportion of patient s
achieving HbA1c targets13.The proportion of patients with HbA1c <7% 
and ≤6.5% at Week [ADDRESS_563661] to the duration of time spent in 
hypoglycemic glucose ranges, obtained from 
CGM use14.Duration (in minutes) and percentage of time 
with glucose values <54 and <70mg/dL ( 3.0
and3.9 mmol/L), normalized to a 24-hour 
period and number of epi[INVESTIGATOR_1841], defined as at 
least 10 consecutive minutes < 54 and
<70mg/dL, from each [ADDRESS_563662] to the duration of time spent in 
hyperglycemic glucose ranges, obtained from 
CGM use15.Duration (in minutes) and percentage of time 
with glucose values >180 and >250 mg/dL 
(10.0 and13.9 mmol/L), normalized to a 
24-hour period and number of epi[INVESTIGATOR_1841], defined 
as at least 10 consecutive minutes >18
0 and
>250 mg/dL, from each 14 -day CGM session at 
Week 16
I8B-MC-ITRO(c)Clinical Protocol Page [ADDRESS_563663] to the incidence and rate of pump 
occlusion alarms that lead to an unplanned 
infusion set change16.Rate (events/ patient /30 days) and incidence 
(percent of patients with at least 1event) of 
pump occlusion alarms that lead to an 
unplanned infusion set change from baseline 
through Week [ADDRESS_563664] to the incidence and rate of 
epi[INVESTIGATOR_443176]17.Rate (events/ patient /30 days) and incidence 
(percent of patients with at least 1event of 
unexplained hyperglycemia > 300 mg/dL 
confirmed by [CONTACT_443193] 16
Abbreviations:  1,5-AG =1,5-Anhydroglucitol; AIT =active insulin time; AUC =area under the curve ;
CGM =continuous glucose monitoring; CR=carbohydrate ratio; CSII =continuous subcutaneous insulin 
infusion; CV=coefficient of variation; EQ-5D-5L = EuroQol 5D -5L; EQ -VAS =EQ visual analog scale; 
HbA1c =hemoglobin A1c; HBGI =high blood glucose index; ISF=insulin sensitivity factor; ITSQ =Insulin 
Treatment Satisfac tion Questionnaire; LBGI =low blood glucose index ; MMTT =mixed meal tolerance test; 
NIM =noninferiority margin; SMBG =self-monitored blood glucose; T1D =type 1 diabetes; [LOCATION_006]=United 
Kingdom .
Summary of Study Design:   
Study I8B -MC -ITRO (ITRO ) is a Phase 3, prospective , randomized, outpatient, multi national, multicenter, 
2-treatment group, parallel, active - controlled, double -blind study conducted in adult patients with T1D currently 
using CSII therapy.
This study involves adult patients who have been diagnosed with T1D for at least one year, have been using CSII 
therapy  without interruption for at least [ADDRESS_563665] an HbA1c value of ≥6.5%and ≤9.0% at screening.  
Patients must be using insulin lispro, insulin aspart, or insulin glulisine in thei r pumps.
Treatment Groups and Duration:   
The study  includes a 1 -week screening peri od and a 2-week lead - in period , followed by a 16 -week treatment period, 
and a 4 -week safety follow -up period.  In the 2treatment groups, LY900014 and Humalog will be given as both 
bolus and basal insulin , bolus doses will be given immediately prior to each meal (0 to 2 minutes) .  
Number of Patients :
Numbers are approximate:  526participants will be screened to achieve 420randomized patients and 368 patients
completing 16 weeks of treatment. 
Statistical Analysis:
The primary analysis is for the treatment period up through Week 16.  
Efficacy analyses will be conducted on all randomized patients according to the treatment the patients areassigned .  
The analy ses for the primary and multiplicity adjusted objectives will be performed for the efficacy estimand 
including data collected prior to permanent discontinuation of investigational product ( IP)and for the intention to 
treat (ITT )estimand inclu ding all data collected through Week [ADDRESS_563666]-baseline measurement are available .  
I8B-MC-ITRO(c)Clinical Protocol Page 11
LY900014Safety analyses will be conducted on the Safety population.  Analyses of adverse events ( AEs)will include [ADDRESS_563667] -treatment may be conducted as needed .  Analyses of safety laboratory 
measurements will be performed on all data collected during the planned treatment per iod,regardless of IP use .  
A graphical approach for multiple comparisons will be used to stro ngly control the overall Type I erro r (2-sided 
alpha level of 0.05) for testing the treatment effect for t he primary  and the multiplicity -adjusted objectives .  
For the US Food and Drug Administration (FDA )submission, the primary analysis method will use the copy 
reference approach to impute missing data based on multiple imputations with a pattern mixture model.  This 
analy sis is for the ITT estimand (treatment regimen estimand) which will include all data collected regardless of IP 
use.  The reference for each treatment group will be from the retrieved dropout patients who discontinue IP but have 
the measurement at the primary endpoint in the same treatment group.  If there are only a limited number of pat ients 
in the reference group as described above that leads to a failure in performing the proposed multiple imputation 
analy sis, the reference will be changed to include all observed data from all randomized patients in the same 
treatment arm who complete the study without missing data.  After imputation, the primary efficacy comparison will 
be based on the contrast between LY900014 and Humalog from the analy sis of covariance (ANCOVA) analy sis of 
change from baseline to Week [ADDRESS_563668] between 
LY900014 and Humalog at Week 16 (Visit 13) from the mixed - effect model repeated measures (MMRM) analysis 
of change from baseline in HbA1c including data collected from all randomized patients prior to permanent 
discontinuation of IP through Week 16 (efficacy estimand) .  
For both primary analysis approaches, LY900014 w ill be declared noninferior to Humalog if the upper limit of the 
2-sided 95% confidence interval (CI) for the least- squares mean difference in the change from baseline in HbA1c for 
LY900014 minus Humalog is below the noninferiority margin (NIM) of +0.4% .  In addition, the 95% CI for the 
treatment difference from the MMRM model will be compared with an alternative (NIM )of +0.3%.  Both estimands 
will be tested at the full significance level of 0.05.  
Hypoglycemia rates will be summarized for periods of1 yearand 100 years (severe hypoglycemia only).  The rate 
of severe hypoglycemia per 100 years will be compared between treatment groups using the empi[INVESTIGATOR_362263] .  For 
each of the other categories of hypoglycemia, the number of hypoglycemia events during a specific period (rate) 
after randomization (for  example , 0-to 4 weeks of treatment period) will be analyzed by [CONTACT_2329] a negative binomial 
regression model including treatment .  An offset defined as the log transformation of treatment exposure in the 
specific period (day s)/365.[ADDRESS_563669] 1 hypoglycemic event in each category (incidence) during a specific period after 
randomization will be ana lyzed using a logistic regression model including treatment .  
Similarly, a negative binomial model and a logistic regression model including treatment will be used to analyze the 
rate of pump occlusion alarms leading to unplanned infusion set changes per [ADDRESS_563670] 1 occlusion alarm (incidence) leading to unplanned infusion set changes, respectively.
I8B-MC-ITRO(c)Clinical Protocol Page 12
LY900014Continuous safety variables, as well as the change from baseline for these variables, will be analyzed by [CONTACT_443194].  For categorical variables, Fisher’s exact test or Pearson’s chi -square test will be used to 
compare treatment groups unless otherwise specified .  
Change f rom baseline t o last -observation -carried -forward endpoints for European Quality of Life – 5Dimensions 5 
Level (EQ-5D-5L) and ITSQ will be analyzed using ANCOVA models .  
I8B-MC-ITRO(c)Clinical Protocol Page 18
LY900014Abbreviations:  AIT =active insulin time; CF=correction factor; CGM =continuous glucose monitoring; CR =carbohydrate ratio; ECG =electrocardiogram; 
eCRF =electronic case report form; ED =early discontinuation; eGFR =estimated glomerular filtration rate; EQ-5D-5L = European Quality of Life – 5 
Dimensions 5 Level; IP =investigational product; ISF=insulin sensitivity factor; ITSQ = Insulin Treatment Satisfaction Questionnaire; IWRS =interactive 
web-response sy stem; MMTT =mixed meal tolerance test; SMBG =self-mon itored blood glucose .
aTelepho ne visits ar e indicated by [CONTACT_317757].
bPatients who have been randomized will be asked to return for the ED visit in a fasting state unless patient is already fasting and at the site when the decision 
to discontinue is made .  Patients who discontinue during the lead -in period prior to randomization who are not already at the sitewill be asked to return for the 
ED in a nonfasting state andall activities should be completed except for laboratory tests and questionnaires.
cRandomization should occur after all Visit 4procedures including MMTT.  If MMTT is rescheduled post Visit 4, randomization should not occur until 
baseline MMTT is completed.  The patient will administer their first dose of study insulin with the first meal after the MMTT has been completed a nd 
randomization has occurred.
dPatients should be advised to remove th eir shoes /coats and empty their pockets before the body weight is obtained.
eVital sign measurements must be taken before obtaining an ECG tracing and before collection of blood samples for laboratory t esting.  These measurements 
should be determined afte r patient s have been seated quietly for at least [ADDRESS_563671] be supi[INVESTIGATOR_17044] 5 to 10 minutes before ECG collecti on and remain supi[INVESTIGATOR_57966].
gOnly for patients using insulin glulisine or insulin aspart .
hLow glucose suspend is referred to as “Threshold Suspend” (530G), “Low Glucose Suspend” (Paradigm Veo), or “Suspend on low” (630G and 640G) .
iRecord infusion set model andcannula length if changed during the study .
jReservoir is filled with Humalog at lead -in (Visit 2 ),IP at randomization (Visit 4), and prestudy insulin at end of treatment (Visit 13) .
kDuring the lead -in period, bas al rates and bolus settings should be evaluated and adjust edif needed.  During the treatment period, basal rates and bolus 
settings should be titrated in order to meet the target BG levels.
lTraining may be repeated at other visits, as needed. 
mGlucose profiles may be obtained from download o fdevice software (CareLink, Dexcom, and Freestyle Libre) .  Patient will be responsible for entering 
glucose values into pump for bolus calculation and to review with investigator .  Four -and 7-point profiles are needed for clinical management only .
nPatients should be instructed to perform two7-point glucose profiles within the week prior to the 3 Visit s.  The 7 - point profile is completed over a 1 -day 
period, preferably on 2 nonconsecutive days (weekdays and weekends).  
oPatients should be instructed to perform three 10 -point SMBG profiles within the 2 weeks prior to the 3visits .  The 10-point profile is completed over a 1 -day 
period, preferably on 2 nonconsecutive days (weekdays and weekends) using the study blood glucose meter .  
pSensors will need to be changed ever y 7 day s during each CGM session.  One receiver will be used for all 3 sessions .  Two transmitters will be supplied; o ne 
for Sessi ons 1 and 2 and onefor Session 3.  Transmitter and re ceiver will be stored at site between sessions .
qAt Visits 4 and 13, remove sensor and transmitter following the completion of the MMTT.
rSites to check data acceptability reports following upload to confirm no major time gaps occurred during each data capture se ssion.  Continuous glucose 
monitoring collection time gaps greater than 3 hours may require further investigation or re -training .
sAt Visits 4 and 6, provide an extra diary for the telephone Visits 5 and 7.
I8B-MC-ITRO(c)Clinical Protocol Page [ADDRESS_563672] at Visit 4 prior to IP exposure, and at other times at the investigator’s discretion .  When required per 
local regulations and/o r institutional guidelines, local pregnancy testing will occur at mandatory times during the study treatment period.
yFollicle -stimulating hormone test must be performed at Visit 1 for a postmenopausal woman who is between 50 and 54 years of age (in clusive) with an intact 
uterus, not on hormone therapy and has had at least 6 months of spontaneous amenorrhea.
zHealth outcomes questionnaires will be administered at the study sites based on the availability of appropriate translations.   The questionnaires should be 
administered prior to other study procedures .
I8B-MC-ITRO(c)Clinical Protocol Page [ADDRESS_563673] ion compared with 
human insulin; however, the consensus is that they are not rapid enough to match carbohydrate 
absorpti on and m any pat ients are unable to achieve optimal glycemic control.  
An ultra -rapid-acting prandial insulin wit h pharmacokinet ic (PK) and pharmaco dynamic ( PD) 
profiles that demonstrate fast er absorption and onset of action, may better match carbohydrate 
absorpti on and l ead to improved postprandial control.  The time act ion profile of a rapid -acting 
insulin could be enhanced through the addit ion of excipi[INVESTIGATOR_443177]/or enhance vascular permeabilit y.  An ul tra-rapid insulin 
woul d be useful in the treatment of ty pe 1 di abetes mellitus ( T1D) and ty pe 2 di abetes mellitus 
(T2D) when delivered by [CONTACT_443195] (MDI s), by [CONTACT_443196] n (CSII) , and in the development of closed loop insulin delivery systems .  
The aim of this study  is to dem onstrate that an ultra -rapid formulation of insulin lispro, 
LY900014, isnoninferior to Humalog on glycemic control as m easured by  [CONTACT_362277] [ADDRESS_563674] ive ingredient, insulin lispro, as well as 2 excipi[INVESTIGATOR_840] 
(treprostinil and citrate) that facilitate rapid absorption of insulin lispro into the blood stream.  
This novel formulat ionresults in earlier gl ucose l owering when compared with Hum alog.  Thi s 
faster glucose lowering response, as demonstrated by  [CONTACT_443197]900014 when 
compared with Humal og,more closely  mimics the time– action profile of normal endogenous 
insulin secret ion.  Thi s enhanced activit y is expected to provide greater glycemic control as 
dosing relat ive to the start of a meal can be reduced when compared with the timing required for 
the currently available rapid-acting insulin analogs .Dosing closer to the start of a meal will 
allow pat ients to better match the needed insulin dose to the ca rbohy drate content of their meal .  
3.3. Benefit/Risk Assessment
In Phase 1 clinical studi es, the assessment of AEs, hypoglycemic events, local tolerabilit y, vital 
signs, physical examinat ion, electrocardi ogram (ECG ), anti -insulin lispro antibodies, and clinical 
laboratory  assessments di d not reveal any  specific ri sks o f LY900014 beyo nd those al ready  
known for Humalog .LY900014 has been well tolerated in both healt hy subjects and patients 
with diabetes m ellitus. Notably, t here have been no clinically significant increases in adverse 
events (AEs) associated with systemic absorption of treprostinil (headache, diarrhea, nausea, jaw 
pain, vasodilatation, rash, edema, and hypotension are described in the Remodulin p rescribing 
information, 2014). Plasma treprostinil concentratio ns were all below the lower limit of 
quant itationafter subcutaneous (SC) administration of LY900014 .  
I8B-MC-ITRO(c)Clinical Protocol Page 21
LY900014Because insulin pump therapy  uses only  rapid -acting insulin, the onset of diabetic ketoacidosis 
(DKA) can occur quickly if insulin delivery  is interrupted.  Diabet ic ketoacidosis devel ops when 
insulin levels are insufficient to meet the body’s basic metabo lic requirements.  Diabet ic 
ketoacidosis is an acute metabo lic co mplication of diabetes characterized by [CONTACT_157710], 
hyperketonemia, and metabo lic acidosis.  Signs and symptoms may include vo miting, abdo minal 
pain, deep gaspi[INVESTIGATOR_157678], increased urination, weakness, confusio n, and occasionally loss of 
consciousness.  There hasbeen onereport of DKA in completed studi es of LY900014. A high 
blood glucose ( BG)that is not responding to a correction bo lus via insulin pump may indicate an 
infusio n set occl usion or insulin pump problem. Patients in the current study  will be provi ded 
with guidance about the management of high BG , including provi sion of urine ketone stri ps,in 
the setting of possible infusio n set occl usion or insulin pump malfunct ion.  Pati ents will also be
provi ded wi th insulin sy ringes as an al ternate m ethod of invest igational product (IP)delivery in 
the event of pump malfunction and disrupti on.  
In Phase 1 clinical studies, LY900014 has consistent ly demo nstrated a faster time –acti on profile 
than Humalog. In patients with T1D or T2D treated with MDI insulin therapy, LY900014 
significa ntly reduced postprandial glucose (PPG excursio ns com pared withHum alog when both 
were dosed by  [CONTACT_443198] a test meal. Two studi es in patients with T1D have been 
completed using CSII in an in -patient setting, both of which have demo nstrated accelerated time 
action. 
More detailed informat ion about the known and expected benefits and risks of Humal ogmay be 
found in the country -specific product labeling ( for example , Pati ent Informati on Leaflet, Package 
Insert, or Summary  of Product Characteri stics). The Invest igator’s Brochure (IB) describes the 
clinical and nonclinical development of LY900014.
Safety evaluation in this study  will include hypoglycemia, treatm ent-emergent adverse event
s
(TEAEs ), serious adverse events ( SAEs ),frequent glucose monitoring, frequent visits, provi sion 
of urine ketone test stripsfor hyperglycemia troubleshooting , blood pressure, and body  weight.  
More informat ion about the known and expected benefits, risks, SAEs ,and reasonably 
anticipated AEs of LY900014 can be found in the IB.  
I8B-MC-ITRO(c)Clinical Protocol Page [ADDRESS_563675] the hypothesis that LY900014 is 
noninferio r to Humalog on glycemic 
control ([NIM =0.4% for HbA1c) in 
patients with T1D using CSII for [ADDRESS_563676] the hypothesis that LY900014 is 
superior to Humalog in controlling 1-hour 
postprandial glucose (PPG) 2.Difference between LY900014 and Humalog in 
the 1 -hour PPG (serum glucose measured 1 
hour after the start of the meal) from a MMTT 
at Week [ADDRESS_563677] the hypothesis that LY900014 is 
superior to Humalog in controlling 2-hour 
PPG 3.Difference between LY900014 and Humalog in 
the 2 - hour PPG (serum glucose measured 2 
hoursafter the start of the meal) from a MMTT 
at Week [ADDRESS_563678] the hypothesis that LY900014 is 
superior to Humalog on improving glycemic 
control (HbA1 c) 4.Difference between LY900014 and Humalog in 
change from baseline to Week [ADDRESS_563679] the hypothesis that LY900014 is 
superior to Humalog in the duration of time 
glucose values within target range 70 to 
180mg/dL (3.9 to 10.0 mmol/L ), obtained 
from CGM us e during 24
-hour period5.Duration (in minutes and percentage of time )
with glucose values between 7 0and 180 mg/dL 
(3.9 and 10.0 mmol/L), both inclusive, 
normalized to a 24- hour period, from each 
14-day  CGM session at Week [ADDRESS_563680] the hypothesis that LY900014 is 
superior to Humalog in the duration of time 
glucose values within target range 70 to 
180mg/dL (3.9 to 10.0 mmol/L ), obtained 
from CGM us e during daytime6.Duration (in minutes and percentage of time )
with glucose values between 7 0and 180 mg/dL 
(3.9 and 10.0 mmol/L), both incl usive, 
normalized to daytime  (0600 hours to 
midnight) , from each [ADDRESS_563681] to the rate of severe hypoglycemic 
events7.Rate (events/ patient /100 years) of severe 
hypoglycemic events from baseline through 
Week [ADDRESS_563682] to the rate and incidence of 
documented postmeal hypoglycemia 8.Rate (events/ patient /year) and incidence 
(percen tof patients with at least 1event) of 
document ed post meal hypoglycemia within 
1and 2hoursafter the start of themeal from 
baseline through Week [ADDRESS_563683] to the rate and incidence of 
documented hypoglycemia9.Rate (events/ patient /year) and incidence 
(percent ageof patients with events) of 
documented hypoglycemic events from baseline 
through Week 16
I8B-MC-ITRO(c)Clinical Protocol Page [ADDRESS_563684] to total, basal, and bolus insulin dose12.Change f rom baseline in bolus/total insulin dose 
ratio at Week [ADDRESS_563685] to the proportion of patient s 
achieving HbA1c targets13.The proportion of patients with HbA1c <7% 
and ≤6.5% at Week [ADDRESS_563686] to the duration of time spent in 
hypoglycemic glucose ranges, obtained from 
CGM use14.Duration (in minutes) and percentage of time 
with glucose values < 54and < 70 mg/dL ( 3.0
and 3.9 mmol/L), normalized to a [ADDRESS_563687] 10 consecutive minutes < 54and 
<70mg/dL, from each [ADDRESS_563688] to the duration of time spent in 
hyperglycemic glucose ranges, obtained from 
CGM use15.Duration (in minutes) and percentage of time 
with glucose values >180 and>250 mg/dL 
(10.0 and13.9 mmol/L), normalized to a 
24-hour period and number of epi[INVESTIGATOR_1841], defined 
as at least 10 consecutive minutes >180 and
>250 mg/dL, from each [ADDRESS_563689] to the incidence and rate of pump 
occlusion alarms that lead to a nunplanned
infusion set change16.Rate (events/ patient /30 days) and incidence 
(percent of patients with at least 1event) of 
pump occlusion alarms that lead to a n
unplanned infusion set change from baseline 
through Week [ADDRESS_563690] to the incidence and rate of 
epi[INVESTIGATOR_443176]17.Rate (events/ patient /30 days) and incidence 
(percent of patients with at least 1event of 
unexplained hyperglycemia > 300 mg/dL 
confirmed by [CONTACT_443193] 16
Tertiary/Exploratory
18.To compare the safety of LY900014 and 
Humalog18.Adverse events, vital signs, chemistry , and 
hematology laborato ry measures
19.To compare the incidenc e of 
treatment -emergent positive anti -insulin 
lispro antibodies for LY900014 and 
Humalog19.Incidence of treatment emergent a nti-insulin 
lispro antibodies 
20.To compare LY900014 and Humalog with 
respect to quality o f life as measured by [CONTACT_72553]-5D-5L20.Change f rom baseline in EQ -5D-5L 
[LOCATION_006]-populatio n-based health state index score 
and EQ -VAS score at Week 16.
21.To compare LY900014 and Humalog with 
respect to diabetes treatment satisfaction as 
measured by [CONTACT_443199]21. Change f rom baseline in ITSQ regimen 
inconvenience and lifestyle flexibility domain 
scores at Week 16
I8B-MC-ITRO(c)Clinical Protocol Page [ADDRESS_563691] to changes in body weight22.Change in weight (kg) from baseline to 
Week [ADDRESS_563692] to the factors affecting dosing in 
pumps24.Actual and change from baseline in factors
affecting dosing in pump (CR, ISF, AIT, and 
frequency  of use of non-normal bolus type 
[Square Wave or Dual Wave]), during the 
16-week treatment period
25.To compare LY900014 and Humalog with 
respect to the p roportio nofpatients
achieving improvement from baseline in 
HbA1c targets25.The proportions of patients with shifts in 
HbA1c to <8% and ≤9%, from baseline to 
Week [ADDRESS_563693] to the glucose variability, obtained 
from CGM use29.Interquartile range, CV, LBGI, and HBGI from 
each 14 -day CGM session at Week 16
Abbreviations:  1,5-AG =1,5-Anhydroglucitol; AIT =active insulin time; AUC =area under the curve ;
CGM =continuous glucose monitoring; CR=carbohydrate ratio; CSII =continuous subcutaneous insulin 
infusion; CV=coefficient of variation; EQ-5D-5L = EuroQol 5D -5L; EQ -VAS =EQ visual analog scale; 
HbA1c =hemoglobin A1c; HBGI =high blood glucose index; ISF=insulin sensitivity factor; ITSQ =Insulin 
Treatment Satisfaction Questionnaire; LBGI =low blood glucose index ; MMTT =mixed meal tolerance test; 
NIM=noninferiority margin; SMBG =self-monitored blood glucose; T1D =type 1 diabetes; [LOCATION_006]=United 
Kingdom .  
I8B-MC-ITRO(c)Clinical Protocol Page 25
LY9000145.Study  Design
5.1. Overall Design
Study  I8B-MC-ITRO (ITRO) is a Phase 3, prospective, rando mized, outpatient, mult inational, 
multicenter, 2-treatm ent group , parallel, active -controlled, double -blind study  conducted in 
patients with T1D currently using CSII th erapy . Patients will be rando mized to receive 
LY900014 or Humalog as both basal and bolus insulin and will administer bol us doses 0 to 2 
minutes prior to meal (pre -meal) .  The study  is designed to demonstrate noninferiorit y of 
LY900014 when co mpared with Humal ogin change in HbA1c from baseline to Week 16, when 
both are used via CSII and bo lus doses are given prior to the start of the meal.  The study  periods 
include 1-week screening , 2-week lead -in, 16-week treatment , and a 4 -week safet y follow-up.  
Patients treated with a rapid-acting insulin analog insulin lispro, insulin aspart, or insulin 
glulisine via CSII will be eligible for inclu sionin the tri al.  All patient s will use Humal og
during the lead- in period.  Those treated with eit her insulin aspa rt or insulin glulisine at 
screening will be transferred to Humalog at Vi sit 2.At Visit 4, pati ents will be rando mized to 
either LY900014 or Humalog with bolusdoses given immediately  prior to each meal .  
Specific elements of this study  design will include collect ion of 10 -point self -monitored blood 
glucose (Secti on [IP_ADDRESS] ), blinded continuous glucose monitoring ( CGM )sessio ns 
(Secti on9.1.4.6 ), and Mixed Meal Tolerance Testing ( Secti on [IP_ADDRESS] .).  
I8B-MC-ITRO(c)Clinical Protocol Page 26
LY900014Study  governance considerations are described in detail in Appendix 3 .  Figure ITRO .1
illustrates the study  design.
Abbreviation: T=Telephone Visits .
aPre-study rapid -acting insulins:  insulin lispro, insulin aspart, insulin glulisine 
via CSII.  At Visit 2, patients on insulin glulisine or insulin aspart will be transferred to 
Humalog .  At Visit 4, patients will be randomized to either LY900014 or Humalog .  
bPatients will discontinue study insulins at Week 16 .
Figure ITRO .
1. Illustration of study design for Clinical Protocol I8B -MC-ITRO .
5.2. Number of Participants
Numbers are approximate:  526participants will be screened to achieve 420rando mized and [ADDRESS_563694] scheduled procedure shown in the Schedule of Activities(Secti on 2, 
Table ITRO. 1.)for the last patient .
5.3.1. Safety Follow -up
Safety follow
-up visit guidelines are as fo llows (see Secti on 2, Tabl e ITRO. 1 .): 

I8B-MC-ITRO(c)Clinical Protocol Page 27
LY900014Patients who discont inue from the study  during the lead -in period (prior to 
rando mizat ion), only need to complete an early discontinuat ion visit.
Patients who discont inue from IP early  will be encouraged to remain in the study
andcomplete all remai ning visit s per the Schedule of Act ivities, incl uding Visi t 
801.
Patient
s who discont inue from the study  early (regardl essofwhether they  
discontinue IP at the same time or have discont inued IP at an earlier visit), shoul d 
complete an early discont inuat ion visit followed by  [CONTACT_443200] -up visi t as 
per the Schedule of Act ivities.
Patients who finish Visit 13without early discont inuat ion of IPshoul d com plete a 
safety follow
-up visit ( Visit 801) [ADDRESS_563695] marker for development a nd 
progression of diabetes complicat ions.  HbA1c is widely accepted by  [CONTACT_443201] 
(HCPs) and regulatory  authori ties.
During the 2-week lead-in period ,the following will occur :
perform  the fi rst 14 -day blinded CGM sessio n, 
assess pat ient proficiency in carbohydrate counting and provide training, and
assess basal rates and bo lus calculator settings and adjust if needed.
During t he 16-week treatment period ,the following should be titrated in order to meet the target 
BGlevels:
pump basal r ates
bolus calculator settings
ocarbohydrate ratios (CR), 
oinsulin sensitivity factors (ISF), and 
oactive insulin time (AIT)
5.5 Justification for Dose
The basal and bolus delivery o f insulin will be determined based on the individual needs of each 
patient.  LY900014 hasthe sam e insulin lispro concentration (100 U/mL) as that of 
commercially  available Hu malo g.  At  the rando mization visit, IP maybe subst ituted for 
Hum alog (used during l ead-in) on a unit -for
-unit basis.  The addit ion of treprostinil to the
I8B-MC-ITRO(c)Clinical Protocol Page [ADDRESS_563696] meals ,which may potentially i ncrease the risk 
for early  postprandi al hypoglycemia with LY900014.  
I8B-MC-ITRO(c)Clinical Protocol Page [ADDRESS_563697] give wri tten inform ed consent (approved by  [CONTACT_443202]  [Lilly] or i ts 
designee and the ethical review board [ERB] governing the site) before being allowed to 
participate in the study  and before any screening assessments are performed .  
Study  investigator(s) will review the patient’s records and/or history  and screening test 
resul ts/measurements to determine if the patientmeets all inclusio n and no exclusio n criteria to 
qualify  for parti cipat ion in the study.  All screening activit ies must be com pleted and reviewed 
before the patientbegins the lead -in period.
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, are not permitted.
6.1. Inclusion Criteria
Patients are eligible to be included in the study  only  if they  meet all  of the following cri teria at 
screening :
Type of Patient and Disease Characteristics
[1] Men or women diagnosed (clinically) wit h T1D for at least [ADDRESS_563698] 1 year
Patient Characteristics
[2]Are at l east 18 y ears of  age 
[3] Have HbA1c values of ≥6.5% and ≤9.0%, as determined by [CONTACT_443203] (Visit 1)
[4] Have a body  mass index (BMI) of ≤35.0kg/m2at screening (Visit 1). 
[5] Male patients:  
a.No m ale contraception required except in compliance wit h specific l ocal 
government study  requi rements
[6] Female pat ients:  
a.Women not of childbearing potential may participate and include those 
who are:
i.infertile due to surgical sterilizat ion (hysterectomy, bilateral 
oophorectomy , or tubal  ligation), congenital ano maly such as 
Mullerian agenesis; 
Or 
ii.postm enopausal –defined as eit her
I8B-MC-ITRO(c)Clinical Protocol Page 30
LY9000141.a wom an 50 to 54 y ears of age (inclusive) with an intact 
uterus, not on hormone therapy  who has had ei ther
a.cessat ion of menses for at least 1 y ear; 
Or
b.at least 6 m onths of spontaneous amenorrhea with a 
follicle -stimulat ing horm one >40 m IU/mL; 
Or
2.a wom an [ADDRESS_563699] 6 months of spontaneous amenorrhea; 
Or
3.a wom an at l east [ADDRESS_563700] acement therapy
b.Women of childbearing potential participating:
i.Cannot be pregnant or intend to become pregnant
ii.Cannot be breast feeding (including the use of a breast pump)
iii.Must rem ain abst inent or use [ADDRESS_563701] ive methods of 
contraception for the ent irety of the study  (See Appendix 5 )
iv.Test negative for pregnanc y at the time of screening (Visit 1).  
Note:  a urine pregnancy test is conducted at Visit 4.  
[7] Have refrigerat ion in the ho me or have ready access to refrigeration for 
storage of insulin 
[8] Are a patient for whom the invest igator has determined can be rando mized 
and maintain the treatment regimens based on their previous medical history  
including insulin dosing regimens, hypoglycemic epi[INVESTIGATOR_1841], and glycemic 
control
Treatment Characteristics
[9]Current ly treated with <[ADDRESS_563702] 30 day s prior to screening;
a.insulin lispro U -100, 
b.insulin aspart, 
c.fast-acting insulin aspart (where approved) ,or 
I8B-MC-ITRO(c)Clinical Protocol Page 31
LY900014d.insulin glulisine 
[10] Have been using CSII therapy  for a minimum o f [ADDRESS_563703] ion, or a “pump ho liday.”
[11] Must be using a MiniMed 530G (US) , Paradigm Revel (US), MiniMed 
630G (US and Canada ), MiniMed 640G or Paradigm Veo (in select 
countri es outsi de the US ), insulin pump for at least the last 90 day s and are 
capable of and willing to 
a.stay on the same pump throughout the study  
b.use study -provided MiniMed insulin pump reservoirs and i nfusio n sets
c.maintain their current bolus delivery speed (standard or quick) for the 
durati on of  the study
d.use carbohydrate counting for meal-related bol us dosing
e.use the pum p’s bo lus calculator (Bol us Wizard ®), including entry  of the 
current glucose value, to determine mealt ime and correction bo lus doses
[12] May be wearing a Medtronic CGM using the “ Threshol d Suspend ” (530G), 
“Low Glucose Suspend” (Paradigm Veo ) “Suspend on low” (630G and 
640G), and/or “Suspend before low” (640G) pump feature.  Beginning with 
the lead -in period (Visit 2) patients must be willing to; 
a.continue “Thresho ld Suspend” (530G) , “Low Glucose Suspend” (Paradigm 
Veo) or “Suspend on low” (630G or 640G) for the duration of the lead -in 
and treatment periods
b.stop “Suspend before low” (64 0G) for the duration of the lead-in and 
treatm ent peri ods.
[13] May be using personal CGM or FGM to self-monitor glucose atstudy entry.  
a.If chooses to continue, must be willing to maintain its use for the 
durati on of  the study .  
b.May not begin use of personal CGM or FGM during the study .
[14] Are capable o f, and willing, to do the fo llowing: 
a.Perform  10-point self -monitored bl ood gl ucose (SMBG), pri or to 
designated visits (patients using a personal CGM or flash glucose 
monitoring (FGM) device must perform 10 -point SMBG with study  
provi ded gl ucose m eter)
I8B-MC-ITRO(c)Clinical Protocol Page 32
LY900014b.Perform  4-and 7 -point glucose profiles prior to designated visit s 
c.Adhere to a routine infusio n set and reservo ir change interval o f every 3 
days 
d. A void use of all products containing acetaminophen or paracetamo l 
while using the study -provi ded Dexcom  CGM
e.Keep records in pat ient study  diaries requi red by [CONTACT_3181]  
f.Receive diabetes education 
g.Com ply wi th requi red study  treatm ent and study  visits
Informed Consent
[15] Have given written informed consent to participate in this study  in 
accordance with local regulat ions
6.2. Exclusion Criteria
Patients will be excluded fro m study  enro llment if they meet any o f the following cri teria at 
screening :
Medical Conditions
[16] Have any other condit ion (including known drug or alcoho l abuse or 
psychiatric disorder including eat ing disorder) that precludes the patient
from following and com pleting the protocol
[17] Have hypoglycemia unawareness as judged by [CONTACT_17062]
[18] Have had more than 1epi[INVESTIGATOR_66677] (defined as requiring
assistance due to neurologically disabling hypoglycemia) within 6 months 
prior to screening
[19] Have had more than 1emergency room  visit or hospi [INVESTIGATOR_443178]  (hyperglycemia or DKA )within 6 months prior to screening
[20] Have cardio vascu lar di sease, wi thin the l ast 6 m onths prior to screening, 
defined as stroke, decompensated heart failure [LOCATION_001] Heart Association 
classIII or IV (CCNYHA 1994 ), my ocardi al infarcti on, unstable angina 
pectori s, percutaneous transluminal coronary  angio plasty or coronary  
arteri al by[CONTACT_9292]
[21] Renal:
a.History  of renal  transplantati on
b.Current ly receiving renal dialysis
c.Serum  creatinine >2.0 mg/dL (177 µm ol/L) at screening , or
d.An estimated glomerular filtration rate of <30mL/min/1.73 m2.
I8B-MC-ITRO(c)Clinical Protocol Page 33
LY900014[22] Hepati c:have obvious clinical signs or symptoms of liver disease ( for 
example, acute or chronic hepat itis, or cirrhosis) , or elevated liver enzyme 
measurements as indicated below at screening:
a.Total  bilirubin level  (TBL) ≥2X the upper limit of normal (ULN) (with 
the except ion of Gilberts Disease) as defined by [CONTACT_2237] ,
Or
b.Alanine aminotransferase (ALT) ≥3X ULN as defined by  [CONTACT_443204] , 
Or
c.Aspartate aminotransferase (AST) ≥3X ULN as defined by [CONTACT_11378]
[23] Malignancy:  have act ive or untreated malignancy, have been in remissio n 
from clinically  significant m alignancy  (other than basal  cell or squam ous 
cell skin cancer) for less than 5 years, or are at an increased risk for 
developi[INVESTIGATOR_51944] a recurrence of cancer in the opi[INVESTIGATOR_3078] n of th e 
investigator
[24] Haveany hypersensit ivity or allergy  to any  of the insulins or excipi[INVESTIGATOR_443179]
[25] Hem atologic:  have had a blood transfusio n or severe blood loss within 
90days prior to screening or have known hemoglobinopathy , anemia that is 
clinically significant based on invest igator judgement , or any  other trai ts of 
known to interfere wit h measurement of HbA1c
[26] Have p resence of clinically significant gastrointestinal disease ( for example ,
clinically active gastroparesis associated with wide glu cose fluctuations; 
includes those with gastric by[CONTACT_6476]) in the opi[INVESTIGATOR_443180]
[27] Have significant lipohypertrophy , lipoatrophy ,or scars wi thin the SCtissue 
in areas of infusio n, in the opi[INVESTIGATOR_3078] n of the invest igator
[28] Have a history  of abscess at an infu sion site wi thin the l ast 90 day s prior to 
screening
[29] Have visio n loss or hearing loss that does not allo w recogni tion of  pump 
screens, alerts and alarms
Prior/Concomitant Therapy
[30] Have used insulin human inhalat ion powder (Afrezza ®) within 30days pri or 
to screening
[31] Are receiving any oral or injectable medicat ion intended for the treatment of 
diabetes other than rapid
-acting analog insulin via CSII in the 90days prior 
to screening.  In the event of interruption of CSII ≤[ADDRESS_563704] ion of bolus and basal insulin is allowed. 
I8B-MC-ITRO(c)Clinical Protocol Page 34
LY900014[32] Glucocorti coid therapy:   are receiving chronic (lasting longer than 14 
consecut ive days) systemic glucocorticoid therapy (including intravenous
(IV), intramuscular ( IM), SC, and oral), but exclud ing topi[INVESTIGATOR_2855], intraocular, 
intranasal, intra-articular, and inhaled preparations), or have received such 
therapy  within 4weeks immediately prior to screening with the except ion of 
replacement therapy  for adrenal  insufficiency
Prior/Concurrent Clinical Tria l Experience
[33] Are current ly enrolled in any other clinical trial invo lving an IPor any  other 
type of medical research judged not to be scient ifically or medically  
compatible with this study
[34] Have part icipated, within the last 30 days in a clinical trial invo lving an IP
[35] Have previously co mpleted or withdrawn fro m this study  or any  other study  
investigat ing LY900014 after receiving at l east 1 dose of the IP   
Other Exclusions
[36] Have an irregular sleep/wake cycle ( for example, patients who sl eep during 
the day  and work during the night)
[37] Are invest igator site personnel directly affiliated wit h this study  and/or thei r 
immediate families.  Immediate family is defined as a spouse, parent, child, 
or sibling, whether bio logical  or legally adopt ed
[38] Are Lilly  empl oyees (including emplo yees, tem porary  contract workers, or 
designees responsible for the conduct of the study )
6.2.1. Rationale for Exclusion of Certain Study Candidates
The use of LY900014 in pediatric patients (<18 y ears of age) will be studied separately .  This 
study  will specifically  examine com parison of LY900014 to Humalog in adult patients using 
CSII .  Criterion [2] defines the populat ion age for the purpose of this study .  Therefore, pediatric 
patients are excluded.
6.3. Lifestyle Restrictions
Patients should be instructed not to donate blood or blood products during the study .  Patients 
shoul d be instructed to avoi d major changes in diet or exerci se during the study .  Pati ents shoul d 
be instructed to avoid all medicat ions that contain acetaminophen/paracetamo l during the blinded 
CGM study sessio ns.  Patients should be instructed to avoi d maj or changes in dietary  intake or 
physical act ivity during the [ADDRESS_563705] (MMTT ).  
6.4. Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen failure) m ay not be 
rescreened , with the except ion of individuals from  select countries who init ially screen failed 
because they  usea Paradi gm Revel  or Paradi gm Veo pum p.  Retests are al so not allowed, except 
for cases when results are unavailable from the original sample.
I8B-MC-ITRO(c)Clinical Protocol Page 35
LY9000147.Treatment s
7.1. Trea tments Administered
This study  involves a doubl e-blind compar ison of LY900014 and Humal og, in patients with T1D
using CSII .  Table ITRO .3shows the treatment regimens .
Table ITRO .3. Treatment Regimens
Regimen Dose StrengthDose 
AdministrationRoute of 
Administration Timing of Dose
LY900014 100 U/mL Individualized
DosingCSII Mealtime bolus 0 -2 min prior 
to start of the meal; continuous 
basal infusion; correction 
boluses as necessary
Humalog 100 U/mL Individualized
DosingCSII Mealtime bolus 0 -2 min prior 
to start of the meal; continuous 
basal infusion; correction 
boluses as necessary
Abbreviation:  CSII =continuous subcutaneous insulin infusion .
The invest igator or his or her designee is responsible for the following:
explaining the correct use of IPto the patient
explaining storage requirements for IP
explaining requirements for recording time and amount of bolus doses to the 
patient
maintaining accurate records of IPdispensing and collect ion
at the end of the study  returning all used and unused IPto Lilly ,or its desi gnee ,
unless the sponsor and sites have agreed all unused medicat ion is to be destroyed 
by [CONTACT_779], as allowed by [CONTACT_1769]
7.1.1. Packaging and Labelling
Clinical trial materials will be labeled as IP as appropriate, and according to the regulatory 
requi rements of the country .  Study  insulins (LY900014 and Hum alog) will be supplied by [CONTACT_443205], in accordance with current good manufacturing practices and will be 
supplied wit h lot numbers.
The blinded vials will contain a concentration of 100 U/ mL in 10 -mL vials o f either LY900014
or Humalog .  
During the l ead-in period, Hum alog100 U/m L will be provi ded in open -label 10 -mL vials.
7.1.2. Insulin Pumps
Patients will use their personal insulin pumps for the duration of the study but will be required to 
use reservo irs and infusio n sets provi ded by [CONTACT_3878].   Pump reservo irs will  be filled 
I8B-MC-ITRO(c)Clinical Protocol Page [ADDRESS_563706] pati ents wi th setting a reminder in their pump to prompt for a reservoir and infusi on 
set change every 3 days.
If a pum p malfuncti on requi resa patientto change to a new insulin pump during the study , it will 
be allowed as long as the new pump
is approved in the country  where the patientresides 
is allowed by[CONTACT_1758] (MiniMed 530G, Paradigm Revel, 630G, Paradigm Veo or 640G)
Training has been provided to the patientby a qualified HCP, and
iscompat iblewitha Contour Link blood glucose meter that
ois approved in the country  where the patient resides and
ocan be sourced by [CONTACT_13099] r for the Study .
[IP_ADDRESS]. Personal Continuous Glucose Monitor Use inStudy
Patients may continue to use the ir personal CGM or FGM during the study . 
Patients will  not be allowed to start using personal CGM or FGM during the study .  In order to 
account for potential differences between pat ients who wear a CGM or FGM and those who do 
not, stratificat ion by [CONTACT_1962]’ personal CGM or FGM use will ensure balance of this factor 
across treatments.  Patients may use their personal CGM or FGM forthe required glucose value
entriesinto the pump bolus calculator for meal and correction bo luses ,if approved in their 
country  for making treatm ent deci sions ( i.e.,nonadjunct ive use) .  Patients will be required to 
perform  SMBG wi th the study  provi ded blood glucose meter for the s tudy procedures described 
in Section [IP_ADDRESS] .
7.1.3. Medical Devices
Study patients will be provi ded with anapproved, compat ible blood glucose meter .  The pati ent’s 
meter m ust be wi relessly connected to their insulin pump.  Instructi ons for connect ing are found 
in the pump and meter user guides and also provided as a site tool.  Once connected, the pump 
autom atically controls the date and time of the meter.  It will also send all BG results direct ly to 
the pump when the“Always” meter send option is selected (recommended ).The BG meter s
used in this study  will be ha vereceived clearance from the Food and Drug Administration ( FDA )
and meet the followin g standard for bl ood gl ucose meters:  ISO [ZIP_CODE]:2013.   At every site visit 
beginning with Visit 2, site staff shoul d verify  synchronizat ion of the dates and times of the 
pump and BG m eter. 
7.2. Method of Treatment Assignment
Patients who meet all criteria for enrollment will be randomized to double -blind treatment at 
Visit 4.  Assignment to treatment groups will be determined by a computer -generated random 
sequence using an interactive web
-response system (IWRS).  The IWRS will be used to assign 
all vials conta ining double -blind IP during the study and open -labelHumal ogduring the l ead-in 
I8B-MC-ITRO(c)Clinical Protocol Page [ADDRESS_563707] vials by  [CONTACT_45342] a 
confirmat ion number found on the vials into the IWRS.
Patients will be randomized t o 1 of 2treatm ent groups in 1:1 ratio.  Stratificat ion will be by 
[CONTACT_1606] , HbA1c stratum  (≤7.5%, >7.5% at Visit 1), and patient’s personal CGM or FGM use 
during the study  (yes/no).  
Patients will begin using double -blind IP in their pumps immediately  following successful 
completion of the Visit 4 MMTT.  Patient s will fill a new pump reservo ir and infusio n set wi th 
IP, then insert a new pump infusio n set cannula and begin infusio n of IP prior to leaving the 
investigat ive site.   
7.2.1. Selection and Timing of Doses
[IP_ADDRESS]. Target Glucose Values for Titration of Insulin Therapy
The overall glycemic control goals for all patients enro lled in the study  are similar to those 
recommended by  [CONTACT_443206] (AACE )(Bailey 
et al. 2016).   Fasting, prandial, bedtime, and peak PPG target val ues used to reach the 
glucose targets and for determinat ion of titration in insulin therapy are listed in Table 
ITRO. 4
Table ITRO. 4. Target Glucose Values for Titration of Insulin Therapy
Time of Measurement Target (Range)
Fasting or pre-morning meal Target:   100 mg/dL or 5.6 mmol/L
Range: 80to<100 mg/dL or 4.4to 6.1mmol/L
Pre-midday  meal Target:   100 mg/dL or 5.6 mmol/L
Range:   80to<110 mg/dL or 4.4to6.1mmol/L
Pre-evening meal Target:100 mg/dL or 5.6 mmol/L 
Range:   80to<110 mg/dL or 4.4to6.1mmol/L
Pre-bedtime and 03:00 AM Range:   90to130 mg/dL or 5.0to7.2 mmol/L
1-2-hour postprandial Target:  < 180mg/dL or 10.0 mmol/L 
[IP_ADDRESS]. Pump Settings
Evaluat ing and titrating pump settings is at the discretion of the investigator and should be done 
with a methodical approach by [CONTACT_443207], insulin delivery settings and 
carbohydrate intake .  During titration of  pum p settings, patients should eat m eals that have 
known carbohydrate content and can be accurate lycounted and avo id snacking between meals 
(unless treating hypoglycemia) .  Pati ents will be allowed to use low glucose suspend for the 
lead-in and durat ion of the treatment period. Patients will not be allowed to use “SmartGuard 
Suspend before low”(Refer Section 6.1Inclusion Criteria [ 12]). 
[IP_ADDRESS]. Basal Rate Titration
At all clinic and tel ephone visit s during the 16-week treatm entperiod fo llowing rando mizat ion, 
titration of  
basal rates shoul d be based on glucose values , hypoglycemia data and determined by 
[CONTACT_443208] n with the patient.   Addit ional discussio n between visit s may be 
I8B-MC-ITRO(c)Clinical Protocol Page 38
LY900014requi red to enable the patient to reach the fasting blood glucose target of 100 mg/dL (5.6 
mmo l/L) and to optimize [ADDRESS_563708] igator; thus ,the prescribed 
basal rates during the study  are determined by, and the responsibilit y of, the invest igator .  
Overnight basal rates should be assessed by  [CONTACT_443209] (bedtime to 
mid-sleep; mid -sleep to awakening) and titrated to match diurnal variations .  When basal rates 
are set correctly, patients should be able to sleep late, eat late , or skip a meal wit hout 
experiencing glucose excursio ns.  
Daytime basal rates can be titrated using either the fast ing method or nonfast ing method. 
If using the fast ing method, e valuate glucose l evels across ski pped -meal t ime segment s
(pre-morning to pre-midday, pre -midday to pre -evening , or pre -evening to bedtime) and
titrate/add basal rate(s) based on the pattern s observed across ski pped -meal times.  
If using the nonfast ing method, e valuate basal rates by [CONTACT_443210] 2-hour postmeal glucose to 
thenext premeal glucose .  
Postmeal glucose should steadily decline and return to premeal target 
range by  [CONTACT_443211] . 
[IP_ADDRESS]. Bolus Dose Titration
Postprandi al glucose l evels fro m 10-point SMBG profiles and 7 -point gl ucose profiles shoul d be 
evaluated by [CONTACT_443212].  Addit ional glucose testing should be 
considered during the day s following transi tion to study  insulin.  Titration of bolus calculator 
settings (CR, ISF, and AIT) during the study  are determined by, and th e responsibilit y of, the 
investigator.  
Patients shoul d use the pum p Bol us Wizard® calcul ator f or cal culat ing bolus and correction 
doses to ensure that the carbohydrate con tent of each meal is covered and the preprandial glucose 
level is accounted for in the preprandial bo lus dose.  
In order to meet the target glucose levels during the 16-week treatment period, the invest igator in 
discussio n with the pati entshoul d; 
Weekly assess and titrate the CR, ISF, and AIT 
oThe CR is used to calculate food bolus amounts.  Evaluate CRs by 
[CONTACT_155897] -meal glucose to i ts corresponding [ADDRESS_563709] -meal 
glucose. The CR may be titrated every 3 -4 day s (twi ce per week) 
when appropriate, based on the patient’s glycemic needs and glucose 
levels.  
oThe ISF i s used to calculate correction bolus amounts that is needed to 
bring the glucose into target range.  
I8B-MC-ITRO(c)Clinical Protocol Page 39
LY900014Weekly discuss and determine optimal  bolus types (normal, square or dual 
wave) for meals of different macronutrient composit ion.  For meals that tend 
to be l arger in size and of higher protein and fat content (often the dinner 
meal), a higher bo lus dose or a dual or square wave bo lus may be appropriate
to prevent late postmeal hyperglycemia .  
[IP_ADDRESS]. Transitioning off Study Prandial Insulin Therapy
Patients will give theirlast bo lus dose of study insulin (LY900014 or Humalog ) at Vi sit 13with 
the MMTT or at early discontinuation .  No speci al instructi ons are necessary  for patients who 
were randomized to either LY900014 or Humalog .  After com pletion of study  treatm ent, patients 
will restart the rapid -acting insulin analog used prior to study entry via CSII and their pumps 
settings will be reset to those used at randomizat ion
.
7.3. Blinding
This is a double -blind study .  LY900014 and Humal ogtreatm ent groups will have prem eal bolus 
doses given via CSII .  Invest igators, patient s, and study  site personnel  will be blinded to assi gned 
dosing regimens throughout the study .  
To preserve the blinding of the study , the Lilly study  team  will remain blinded throughout the 
study; only  a minimum number of Lilly personnel will see the rando mizat ion table and treatment 
assignments before the study  is com plete .  
Emergency  unblinding for AEs m ay be perform ed through the IWRS.  This option may  be used 
ONLY if the patient’s well -being requires knowledge of the patient ’s treatm ent assi gnment.  
Unblinding events are recorded and reported by  [CONTACT_8784] .  
If an invest igator, site personnel performing assessments, or patient is unblinded, the patient
must be discont inued fro m IPand should remain in t he study .  
In case of an emergency , the invest igator has the sole responsibilit y for determining if unblinding 
of a patient’s treatment assignment is warranted.  Patient safet y must always be the first 
consideration in making such a determinat ion.  If the invest igator decides that unblinding is 
warranted, the invest igator should make every effo rt to con tact the Lilly clinical research 
physician/clinical research scient ist (CRP/CRS) prior to unblinding a patient’s treatm ent 
assignment unless this could dela y emergency treatment of the patient.  If a patient’s treatm ent 
assignment is unblinded, Lilly must be notified immediately.
7.4. Dosage Modification
See Secti on 7.2.1 .
7.5. Preparation/Handling/Storage/Accountability
The invest igator or his or her designee is responsible for confirming appropriate temperature 
condi tions have been maintained during transit for all study  treatm ent received and any 
discrepancies are reported and resolved before use of the study  treatm ent.  
I8B-MC-ITRO(c)Clinical Protocol Page 40
LY900014Only participants enro lled in the study  may receive IP ,and only authorized site staff may supply 
or administer study  treatm ent.  All  study  treatm ents shoul d be stored in an environmentally  
controlled and mo nitored (manual or automated) area in accordance with the labeled storage 
condi tions wi th access limited to the invest igator and authorized site staff.
All insulin products must be stored at the invest igative site under refrigerated condit ions 
(between 2°C and 8°C) in a locked and secure place.  Insulin must not be frozen.
Vials o f insulin not currently in -use shoul d be refrigerated un til ready  to use.  In-use insulins 
shoul d be maintained at room temperature (between 2 0°C and 25°C )when possible and 
refrigerated material should be warmed to near room temperature before infusio n.  In -use insulin 
must not be used after [ADDRESS_563710] 
maintenance ( such as receipt, reconciliat ion
, and final disposit ion records) .  
7.6. Treatment Compliance
The invest igator or designee will assess compliance of the patient at each visit, based on a review 
of the patient’s glycemic control, adherence to the visit and treatment schedule, and complet ion 
of the patient’sstudy  diary.  Pati ents who are deemed nonco mpliant will receive addit ional 
diabetes educat ion and training, as required, and the importance of compliance wi th the protocol  
will be reinforced.  Patients who, in the opi[INVESTIGATOR_1649] o f the invest igator, are deemed consistent ly 
nonco mpliant may be discont inued fro m IP.  
7.7. Concomitant Therapy
The fo llowing concomitant medicat ions 
are NOT allowed at any t imeduring the stu dy; 
oAny noninsulin diabetes treatment therapy
oAfrezza ®(inhaled insulin) 
Are NOT allowed during the blinded CGM sessio ns; 
oMedicines containing Acetaminophen /paracetam ol
ARE allowed forup to a total of 7 day s during the lead -in period and 14days 
during the treatment period ;  
oSystemic glucocorti costeroi ds
IV, IM , SC, oral 
except in the case of replacement therapy  for adrenal  
insufficiency
ARE allowed for 14days or less during the study
oBasal insulin
I8B-MC-ITRO(c)Clinical Protocol Page 41
LY900014oRegular human insulin or a nonstudy  rapid-actinganalog insulin
ARE allowed at any  time
oTopi[INVESTIGATOR_2855], inhaled, intraocul ar, intra-articular, or intranasal steroi d 
preparati ons
7.8. Treatment after the End of the Stu dy
7.8.1. Treatment after Study Completion
LY900014 will not be made available to patients after concl usion of  the study .  Rapi d-acting 
insulin analogs and regular human insulin are available in all countries for use as prandial /pump
insulin .  
7.8.2. Special Treatment Considerations
After di scontinuat ion of IP at the end of the treatment period or earlier, randomized patients 
shoul d restart the rapid-acting analog insulin used prior to study entry .  
Invest igators should provide pat ients with appropri ate gui dance for glucose monitoring and 
insulin dose adjust ment throughout the fo llow
-up peri od in order to m aintain glycemic control .
I8B-MC-ITRO(c)Clinical Protocol Page [ADDRESS_563711] ion.  Thi s study includes elements to 
minimize missing data.  Patient s who are discontinued fro m IPbefore study  com pletion are 
encouraged to remain in the study  for continued moni toring.  For patient s who remain in the 
study  after early  discontinuat ion of IP, both efficacy (HbA1c) and safet y data will be co llected at 
scheduled visits.  The difference between stoppi[INVESTIGATOR_443181] s tudy will be 
explained to patients as part of the informed consent, and patients will be encouraged to continue 
in the study  even if they  stop study  drug.  In addi tion, study  site investi gators will betrained on 
the importance of complete data collect ion,with addi tional re-educat ion of sites and patientsas 
necessary .  
8.1.1. Permanent Discontinuation from Study Treatment
Patientswill be discont inued fro m the IPin the following circumstances :
The invest igator may decide that the patient shoul d stop IP.  If thi s decisio n is 
made because of an AE, SAE ,or a clinically significant laboratory  value, the 
study  drug i s discont inued for that patient and appropriate measures are to be 
taken.  Lilly or its designee is to be alerted immediately.
The patientmay decide to stop IP .  
If the patient becomes pregnant.
If an invest igator, study site personnel performing assessments, or patient is 
unblinded, the patientmust discont inue IP.  
If the patient, for any  reason, requi res treatm ent with anothe r therapeuti c 
regimen or therapeutic agent that has been demonstrated to be effect ive for 
treatm ent of the study  indicat ion.  Discont inuat ion fro m IP shoul d occur pri or 
to introduction of the new agent .
Use of prohibited conco mitant m edicat ion (Guidance on restrict ions for 
concomitant therapi[INVESTIGATOR_443182]7.7).
Use of pump that is not allowed .
If the patient has not used IP for more than 14daystotal. 
If the patient experiences a second epi[INVESTIGATOR_443183] a hepatic event or liver test abnormality.   Patients who are 
discontinued fro m IPdue to a hepatic event or liver test abnormalit y shoul d have addi tional 
hepat ic safet y data collected via case report form (CRF ).
I8B-MC-ITRO(c)Clinical Protocol Page [ADDRESS_563712] igator
when a patient meets one of the f ollowing condi tionsafter consul tationwith the Lilly 
designated medical mo nitor.  
ALT or AST >8X ULN
ALT o r AST >5X ULN for more than 2 weeks
ALT or AST >3X ULN and TBL >2X ULN or prothrombin t ime >1.5X ULN
ALT or AST >3X ULN with the appearance of fatigue, nausea, vo miting, 
right upper -quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
alkaline phosphatase (ALP) >3X ULN
ALP >2.5X ULN and TBL >2X ULN
ALP >2.[ADDRESS_563713] with the appearance of fatigue, nausea, vo miting, right 
quadrant pain o r tenderness, fever, rash, and/or eosinophilia (>5%)
Patients di scont inuing fro m the IPprematurely for any reason should co mplete AEand other 
follow-up procedures per Section 2(Schedule of Activit iesTable ITRO.1. ), Section 9.2(Adverse 
Events), and Section 9.4(Safet y) of this protocol .
8.1.2. Temporary Discontinuation from Study Treatment
Patients can have temporary  
discont inuat ionofIP for up to a total of 14 days (consecut ive or 
nonconsecut ive).  
In the event of a pump failure, MDI therapy  is allo wed for ≤14days.  Bolus and basal insulin 
will be determined by [CONTACT_443213] .  When possible ,continuing on IP is 
preferred.  Invest igationalproduct may be wit hdrawn f rom the vial and injected as needed to 
cover meals and correct hy perglycemia using the insulin syringes provided.  
8.1.3. Discontinuation of Inadvertently Enrolled Patient s
If the sponsor or invest igator ident ify a pat ientwho did not meet enrollment criteria an d was 
inadvertent ly enro lled, then the patient should be discontinued fro m study  treatm ent unless there 
are extenuat ing circumstances that make it medically necessary for the patient to continue study 
treatm ent.  If the invest igator and the sponsor CRP agr ee it is medically appropriate to continue, 
the invest igator must obtain documented approval fro m the sponsor CRP to allow the 
inadvertent ly enro lled patientto conti nue in the study  with or wi thout treatm ent wi th IP. Safet y 
follow
-up is as outlined in Section 2(Schedule of Act ivitiesTable ITRO. 1.), Secti on 9.2
(Adverse Events), and Section 9.4(Safet y) of the protocol .
8.2. Discontinuation from the Study
Some possible reasons that may  lead to perm anent di scontinuat ion include the following :
Enrollment in any other clinical trial invo lving an IPor enrollment in any 
other ty pe of medical research judged not to be scient ifically or medically 
compatible with this study
I8B-MC-ITRO(c)Clinical Protocol Page 44
LY900014Participation in the study  needs to be stopped for medical, safet y, regul atory , 
or other reasons consistent with applicable laws, regulat ions, and good clinical 
practi ce (GCP)
The invest igator decides to discont inue the patientfrom the study
The patientrequests to be discontinued from the study
The patient discont inues Hum alogregimen for > 3consecut ivedays in the 
lead-in period
Patientsdiscont inuing fro m the study  prem aturely for any  reason shoul d com plete AEand other 
safet y follow-up per Secti on 2(Schedule of Ac tivitiesTable ITRO.1. ), Section 9.2(Adverse 
Events), and Section 9.4(Safet y) of this protocol .  Patients who discont inue during the lead
-in 
period will not need to fast, have lab oratory  tests drawn, or complete questionnaires, but will 
have all other early discont inuat ion procedures performed .  Site shoul d docum ent details 
regarding the reason for discont inuat ion when av ailable .  
8.3. Lost to Follow -up
A patientwillbe considered lost to fo llow-up if he or she repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by  [CONTACT_4145].  Site personnel are expected to make 
diligent attempts to contact [CONTACT_57986] a scheduled visit or were otherwise 
unable to be fo llowed up by  [CONTACT_4179].  Due diligence efforts should be documented in electroni c 
case report form (eCRF ).  
I8B-MC-ITRO(c)Clinical Protocol Page [ADDRESS_563714] ivities (Table ITRO. 1.), with the study procedures and their 
timing (including tolerance limit s for timing).
Appendix [ADDRESS_563715] results.  Certain samples may 
be retained for a longer period, if necessary, to comply wit h applicable laws, regulat ions, or 
laboratory  certificati on standards.
9.1. Efficacy Assessments
9.1.1. Primary Efficacy Assessments
The primary  efficacy  measure is the change from baseline to Week 16 in HbA1c.
9.1.2. Secondary Efficacy Assessments
The fo llowing secondary  efficacy measures will be collected at the times shown in the Schedule 
of Activities (Secti on 2).  
Fasting and PPG collected during the MMTT :
o1-hour and 2 -hour PPG :  serum glucose measured 1 hour and 2 hours 
after the start of themeal 
oIncremental  areas under the serum glucose concentrati on-time curve 
from 0 to 30 minutes, 0 to 1 hour, 0 to 2 hours, 0 to 3 hours, and 0 to 
4hours after a meal; maximum serum  glucose after a m eal
oGlucose vari ability measured by [CONTACT_443214](SD)
1,5-Anhydroglucito l (1,5-AG)
SMBG 10 -point profiles:
o1-hour and 2 -hour PPG and PPG excursio ns by [CONTACT_443215]-and between -day gl ucose variabilit y measured by [CONTACT_443216]
CGM
oDurati on and percentage of time in range (70-180 mg/dL [ 3.9-
10.0 mmo l/L]
)during the day time (0600 hours to midnight) and 24 -
hour peri odobtained by [CONTACT_3449] -provi ded Dexco m blinded CGM
oDurati on and percentage of time with glucose values <54 and 
<70mg/dL ( 3.0and 3.9 mmo l/L)
I8B-MC-ITRO(c)Clinical Protocol Page 46
LY900014oDurati on and percentag e of time wi th glucose values >180 and
>250 mg/dL (10.0 and13.9 mmo l/L)
Proporti on of  patient s with HbA1c ≤6.5% and<7.0% 
Bolus, basal  and total  insulin dose (units and units/kg) and bolus/total insulin 
ratio 
9.1.3. Appropriateness of Assessments
All efficacy and safet y assessments included in this study  are generally regarded as reliable and 
accurate with respect to diabetes.
9.1.4. Study Procedures
The fo llowing procedures will be performedat the times shown in the Schedule of Act ivities 
(Secti on 2).  
[IP_ADDRESS]. Use of Personal CGM or FGM
Patients m ay continue to use their personal CGM or FGM throughout the study (Secti on [IP_ADDRESS]).  
Patients will be allowed to use their personal  CGM/FGM for the 4 -and 7 -point glucose profiles
(as consistent with local regulat ions and standard of care )
,and thenenter the sensor glucose 
values into the irpump.  If  patients do not have a personal CGM/FGM ,they will be requi red to 
perform  the 4 -and 7 -point glucose profiles using the study  provi ded BG meter andthese gl ucose 
values will be automat ically transferred to the pump . The 4 -and 7 -point values are required at 
the time sdescribed in Table ITRO. 5.
[IP_ADDRESS]. Collection of Glucose Profiles
Patients will  be asked to collect [ADDRESS_563716] 
nonco mpliance wit h the protocol.   
During the 10
-point SMBG profiles, p atients should be encouraged to eat meals in the morning, 
midday , and evening (and eat a snack if that is their usual practice ).
I8B-MC-ITRO(c)Clinical Protocol Page [ADDRESS_563717] in Patient D iary when; 
SMBG is >300 mg/dL, 
nausea , vomiting, or abdominal pain is present ,
an illness occurs .
If moderate or l arge am ounts of  urine ketones are present, patients should notify  the invest igator 
immediately  and go to the Em ergency Room .
[IP_ADDRESS]. Blinded Continuous Glucose Monitoring Sessions
The Dexco m G5 Mobile Cont inuous Glucose Monitoring System (Dexco m G5) will be used by 
[CONTACT_443217] 14 day s prior to Vi sits 4, 10, and 13 .  The Dexco m G5 is an 
FDA -approved and European Unio n European Conformit y (CE) l abelled device, develope d for 
continuous monitoring of interstitial glucose l evels in persons with diabetes mellitus .  Prior to 
each blinded CGM sessio n, site staff shoul d verify thedate and time of the Dexcom G5 Receiver 
and adjust if needed .  Pati ents will be instructed to change the Dexco m G5 sensor every  [ADDRESS_563718] label. Patients will  receive training on the use of the Dexcom G5 and 
will be expected to complete daily requirements .  
Patients will  need to consider the se cond 7 -day end time of the baseline and endpoint sensor 
sessions so that they are able to continue to wear the blinded CGM during both MMTTs.   If the 
second sensor is scheduled to end on the day  ofthe MMTT, the patient should end the sensor 
session and in sert a new sensor the evening prior to the scheduled time of the MMTT.
Daily Requirements for Patients during each Blinded Dexcom G5 Session
Eat a similar breakfast each day and avoid snacking for the 2-hour period after 
breakfast unless it is necessary  totreat hy poglycemia.
Enter date and start time of all meals into the Patient Diary  
Enter date and start time of bedtimesnack, if consumed, into the Pati ent Di ary 
Keep the Dexco m G5 Receiver close to the body
owithin about 6 m eters (about 20 feet) of the Dexcom G5 Transmi tter, 
owithout obstructi on, to minimize the loss of transmitted data.
Calibrate the Dexco m G5 Se nsor every  12 hours.
oUse SMBG values taken only fro m finger -sticks for calibrat ions.  
oDo not use alternat ive BG site testing (forearm, palm, etc.) for sensor 
calibrat ion.
Avoid products containing acetaminophen/paracetamo l while using the 
Dexco m G5.
I8B-MC-ITRO(c)Clinical Protocol Page [ADDRESS_563719]
A 4-hour  MMTT will be performed in all patients at 
baseline (Week 0, Vi sit 4) and 
the end of the treatment period (Week 16, Visit 1
3).
The MMTT can
occur 0 to 4 days prior to Visit 4or Visit 13, but as cl ose to the Vi sit date as 
possible. 
be rescheduled up to 2 times within the visit window, ideally at 24 -hour 
intervals, if the pat ient does not meet the target FBG. 
occur after a non -severe hypoglycemic epi[INVESTIGATOR_443184] [ADDRESS_563720] meal if it is treated and 
resolved wit h 20 grams or less of carbohy drate
The MMTT cannot occur
if a correction bo lus dose was given less than [ADDRESS_563721] m eal.
if non-severe hypoglycemic epi[INVESTIGATOR_1907] [ADDRESS_563722] meal requires more than 20 grams of 
carbohydrate, or
if pat ient has an epi[INVESTIGATOR_443185] 24 hrs .
The day prior  to the MMTT , patients will be instructed to 
follow norm al eating and exercise routines 
refrain fro m intake of alcoho l
The evening prior  tothe MMTT , patients will be instructed to
fast for at least 8 hours prior to scheduled testing
fill a new pump reservo ir and infusio n set 
owith open -label Humal og-Visit 4
owith IP -Visit 1 3
insert a new infusio n set into an appropriate site
The morning of scheduled MMTT , patients will be instructed to 
measure SMBG at 4 AM
oThis SMBG value should be used by [CONTACT_443218] a 
correcti on bo lus or the intake of no more than 20 grams of 
carbohydrate to arrive at the investigator site with a BG between 
71and 180 mg/dL prior to the MMTT. 
keep programmed basal rates 
continue to wear the CGM device until the end o f the MMTT
I8B-MC-ITRO(c)Clinical Protocol Page 51
LY9000149.1.4.8. Diabetes Education and Nutritional Counseling
Initial training at Visit 2 will include diabetes education and nutrition counseling.  Patients may 
be provided additional training and education at visits fo llowing Visi t 2, based on individual
needs.  Appropriate site personnel will provide training and education using locally  approved 
diabetes educat ion/training materials and programs or by  [CONTACT_443219].  
Training will include
reviews of: 
correct pump use 
o3-day frequency of routine reservo ir and infusio n set changes, 
opriming of the infusio n set, 
oinfusio n site rotation, 
ouse of temporary  basal  rates and alternate bolus type s
carbohydrate coun ting, 
calculat ingbolus and correcti on doses , and
treatinghypoglycemia. 
managing hyperglycemia
9.2. Adverse Events
Invest igators are responsible for monitoring the safety of patients who have entered this study  
and for al erting Lilly  or its des ignee to any  event that seems unusual, even if this event may be 
considered an unant icipated benefit to the patient.
The invest igator is responsible for the appropriate medical care of patientsduring the study.
Invest igators must document their review of each laboratory  safety  report.
The invest igator remains responsible for all AEs through an appropriate healt hcare opti on.  All 
AEs will be fo llowed unt il restoration or until a stable condit ion has been achieved. The 
follow
-up shoul d not be interrupted, even if there is a reasonable explanat ion for the event.
Lack of drug effect is not an AE in clinical studies, because the purpose of the clinical study is to 
establish treatment effect.
After the informed consent form ( ICF) is signed, study site personnel will record vi a electroni c 
data entry  the occurrence and nature of each patient’s preexist ing condit ions, including clinically  
significant si gns and symptom s of the disease under treatment in the study .  In addit ion, site 
personnel will record any  change in the condit ion(s) and any new condit ions as AEs . 
Invest igators should record their assessment of the potential relatedness of each AE to protocol 
procedure, IP, via electronic data entry .  
I8B-MC-ITRO(c)Clinical Protocol Page [ADDRESS_563723] igator will interpret and document whether or not an AE has a reasonable possibilit y 
of being related to study  treatm ent, study  device, or a study  procedure, taki ng into account the 
disease, concomitant treatment or pathologies .  
A “reasonable possibilit y” means that there is a cause and effect relat ionship between the IP, 
study  device and/or study  procedure and the AE.
The invest igator answers yes/no when making this assessment.
Planned surgeries and nonsurgical intervent ions should not be reported as AEs unless the 
underlying medical condit ion has worsened during the course of the study .
If a patient ’s IPis discont inued as a result of an AE, study  site personnel  must report thi s to Lilly 
or its desi gnee via electroni c data entry , clarifying if possible, the circumstances leading to any  
dosagemodificat ions, or discont inuat ions of treatment .  
9.2.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in one of the fo llowing outcom es:
Death
Initial or prolonged inpat ient hospi [INVESTIGATOR_3094]
Alife-threatening experience (that is, immediate risk of dying)
Persistent or si gnificant disabilit y/incapacit y
Congeni tal anom aly/bi rth defect
Important medical events that may not be immediately  life-threatening or result in 
death or hospi[INVESTIGATOR_3092] m ay jeopardize the patient or may  require intervent ion 
to prevent one of the other outcomes listed in the definit ion above.  Examples of 
such m edical events include allergic bronchospasm requiring intensive treatment 
in an em ergency room  or at hom e, blood dy scrasias or convulsions that do not 
resul t in inpat ient hospi [INVESTIGATOR_3094], or the development of drug dependency  or drug 
abuse.
When a condit ion related to the pump necessitates medical or surgical 
intervent ion to preclude either perm anent impai rment of  a body  functi on or 
perm anent dam age to a body  structure, theserious outcom e of “requi red 
intervent ion” will be assigned.
Severe hypoglycemia events :  Epi[INVESTIGATOR_443186] 9.4.[ADDRESS_563724] 
be reported as SAEs
AllAEs occurring after si gning the ICF are recorded in the CRF .The SAE reporting begins 
after the patienthas signed the ICF and has received IP.  However, if an SAE occurs after 
signing the ICF, but prior to receiving IP, the SAE should be reported to the sponsor according to 
SAE -reporti ng requirements and t imelines if it is considered reasonably possibly related to study 
procedure.
I8B-MC-ITRO(c)Clinical Protocol Page [ADDRESS_563725] addi tional data collected using the 
CRF.
Pregnancy ( during maternal or paternal exposure to IP) does not meet the definit ion of an AE.  
However, to fulfill regulatory  requi rements ,any pregnancy  should be reported following the 
SAE pr ocess to collect data on the outcome for both mother and fetus.
Invest igators are not obligated to actively seek AEs or SAEs in patients once they  have 
discontinued and/or completed the study  (the patientsummary CRF has been co mpleted).  
However, if the invest igator learns of any SAE, including a death, at any time after a patienthas 
been discharged from the study , and he or she considers the event reasonably possibly related to 
the study  treatm ent or st udy participation, the investigator must promptly notify Lilly.
[IP_ADDRESS]. Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) are serious events that are not listed 
in the IB and that the investigator ident ifies as related to IPor procedure.  [LOCATION_002] 21 CFR 
312.32 and European Unio n Clinical Trial Directive 2001/20/EC and the associated detailed 
guidances or nati onal regulatory  requi rements in parti cipat ing countries req uire the reporting of 
S[LOCATION_003]Rs.  Lilly has procedures that will be fo llowed for the ident ificat ion, recording and 
expedited reporting of S[LOCATION_003]Rs that are consistent with global regulat ions and the associated 
detailed guidances.
9.2.2. Complaint Handling
Lilly co llects product com plaints on IPsand drug delivery  systems used in clinical studies in 
order to ensure the safet y of study  partici pants, m onitor quali ty, and to facili tate process and 
product improvements .  
Patients will be instructed to contact [CONTACT_443220] a complaint or problem with the IPor their insulin pump so that the si tuation can 
be assessed .  Any insulin pump i ssue will be assessed at the invest igative site and if not resolved ,
the invest igator sh ould report t he complaint directly  to the pump manufacturer in accordance 
with the product labeling. Invest igators should report th ese com plaint s as they  woul d for 
products in the marketplace. 
Com plaint s on IP must be reported to Lilly  by [CONTACT_157720] 24 hours of 
notification, or within 24 hours of study /site personnel becoming aware of a 
product issue, regardless of the availabilit y of the com plaint sample .
Invest igative sites must retain the IP under appropriate storage conditions, if 
available or when obtained, unt il instructed to return it to Lilly .  
Product complaints for Non -Lilly Products (including conco mitant drugs and 
insulin pumps ) that do not have a Lilly Product Batch or Control number are 
reported direct ly to the manufacturer per product lab el.
I8B-MC-ITRO(c)Clinical Protocol Page 54
LY900014Follow the instructi ons outlined in the Product Complaint Form for other 
reporting requirements.
9.3. Treatment of Overdose
Excess insulin administration may result in hypoglycemia.  Refer to the IB for LY900014 and 
product label for Hum alog.
9.4. Safety
9.4.1. Hypogly cemia
Patients will be required to perform  SMBG when hypoglycemia issuspected through
symptoms experienced , 
personal CGM or FGM readings, or
a perceived increased risk as related to 
odietary  intake, 
ophysical act ivity,or
oinadvertent or aty pi[INVESTIGATOR_362272].  
All patient s will be instructed to treat a BG ≤70 mg/dL (3.9 mmo l/L) as hypoglycemia.
If a hypoglycemia event is suspected, the patient should record the BG value, any associated 
symptoms, and the treatment administered in the study  diary .  The pati ent shoul d contact [CONTACT_157722] .  All  hypoglycemia events (severe and nonsevere) mus t be reported on the 
hypoglycemia eCRF.  All epi[INVESTIGATOR_1841] o f severe hypoglycemia must be confirmed by [CONTACT_443221].  
Epi[INVESTIGATOR_443187] d not be 
reported as an AE.  
Hypoglycemia will be described using the following definit ions:
Documented Glucose Alert ; BG ≤70 mg/dL (3.9 mmol/L ):  
oDocum ented symptom atic hypoglycemia :  an event withtypi[INVESTIGATOR_443188]. 
oDocum ented asymptom atic hypoglycemia :  an event without t ypi[INVESTIGATOR_443189]. 
oDocum ented unspecified hypoglycemia:  with no inform ation about 
symptoms of hypoglycemia available ( this has also been called 
unclassifiable hypoglycemia) .
Documented Clinically Significant Hypoglycemia with similar criterion as 
above except for threshold BG <54 mg/dL (3.0 mmol/L )
oDocum ented symptom atic hypoglycemia 
I8B-MC-ITRO(c)Clinical Protocol Page 55
LY900014oDocum ented asymptom atic hypoglycemia
oDocum ented unspecified hypoglycemia
Probable Symptomatic Hypoglycem ia:  an event during which symptoms 
are present, but BG measurement was not reported. 
Severe Hypoglycemia :  during these epi[INVESTIGATOR_1841], patient sha vean al tered m ental  
status and cannot assist in theirown care, may be semiconscious or 
unconscious, or experien ce coma wi th or wi thout sei zures, an d the event 
requi ring assistance of another person to actively administer carbohy drate, 
glucagon, or other resuscitative act ions.  B lood gl ucose measurements m ay 
not be available during such an event, but neurological re covery  attributable to 
the restoration of BG concentration to normal is considered sufficient 
evidence that the event was induced by a low BG concentration (BG 
≤70mg/dL [3.9 mmo l/L]). 
Other Hypoglycemia
oNocturnal Hypoglycemia :  any documented hypoglycemi c event 
(including severe hypoglycemia) that occurs between bedt ime and 
waking.  
oOverall (or Total) Hypoglycemia :  this category combines all cases 
of hypoglycemia (docum ented hypoglycemia andprobable
symptomatic hypoglycemia, including severe hypoglycemia)
excluding the events ofrelative hypoglycemia .  Nocturnal and severe 
hypoglycemia are special cases of documented or probable 
hypoglycemia . If an event of hypoglycemia falls into mult iple 
subcategori es, the event is only counted once in this category .
9.4.2. Severe Hypoglycemia
The determinat ion of a hypoglycemic event as an epi[INVESTIGATOR_66677], as defined 
above, is made by [CONTACT_443222] a patientsimply having received assistance.
9.4.3. Electrocardiograms
For each patient, an ECGs should be performed at Visit 1 according to the study -specific 
requi rements described in the Schedule of Activit ies (Secti on 2, Table ITRO. 1.).  
ECGs will be interpr eted by  a qualified physician (the invest igator or qualified designee) at the 
site as soon after the time of ECG collect ion as possible, and ideally while the patientis still 
present, to determine whether the patientmeets entry  criteria and for immediate patient 
management, should any clinically relevant findings be identified. 
ECGs m ay be obtained at addit ional times, when deemed clinically necessary.
I8B-MC-ITRO(c)Clinical Protocol Page 56
LY9000149.4.4. Vital Signs
For each patient, vital sign m easurements shoul d be conducted according to the Schedule o f 
Activities (Section 2, Table ITRO.1. ) including the study - specific requirements.
9.4.5. Laboratory Tests
For each patient, laboratory testsdetailed in Appendix 2 shoul d be conducted accordi ng to the 
Schedule of Activities (Secti on 2, Table ITRO.1. ). 
Any clinically  significant findings from laboratory tests that resu lt in a diagnosis and that occur 
after the patientreceives the first dose of IPshoul d be reported to Lilly  or its designee as an AE
via electronic data entry .
9.4.6. Safety Monitoring
Lilly will periodically review evolving aggregate safet y data wi thin the study  by [CONTACT_82393].
[IP_ADDRESS]. Hepatic Safety Monitoring
If a study  patient experiences elevated ALT ≥3X ULN, ALP ≥2X ULN, or elevated TBL ≥2X 
ULN, liver testing ( Appendix 4 ) shoul d be repeated wi thin [ADDRESS_563726], TBL, and ALP should 
continue u ntil levels normalize or return to approximate baseline levels. 
Hepatic Safety Data Collection
Addit ional safet y data should be co llected via the eCRF if1 or m ore of the fo llowing condi tions 
occur: 
Elevat ion of serum ALT to ≥5X ULN on 2 or more consecu
tive blood tests
Elevat ion ofserum  TBL to ≥2X ULN (except for cases of known Gilbert’s 
syndro me)
Elevat ion of serum ALP to ≥2X ULN on 2 or more consecutive blood tests
Patient discont inued from treatment due to a hepatic event or abnormalit y of 
liver tests
Hepati c event consi dered to be a SAE
9.5. Pharmacokinetics
Not applicable
9.6. Pharmacodynamics
Not applicable
I8B-MC-ITRO(c)Clinical Protocol Page [ADDRESS_563727] ivities (Secti on 2, Table ITRO. 1).  
Immunogenicit y will be assessed by  a validated radi o ligand -binding assay  (RBA) to detect 
anti-insulin lispro ant ibodies in the presence o f lispro.  Instead of quant itating the level of 
anti-insulin lispro ant ibodies by t iter, the RBA reports a semiquant itative percent -binding for 
each posit ive sample.  Addit ionally , posi tive samples will be characterized for cross -reactive 
binding to native insulin .  
Clinical and reliable on -market data indicate that the immunogenic potential of insulin lispro is 
comparable to other marketed insulins such as regular human insulin (Fineberg et al .  1996) and, 
when present, anti -insulin antibodies do not appear to be clinically consequent ial (Fineberg et al . 
2003).  Therefore, rather than relying on an in vitro neutralization assay, well established in vivo 
measures of insulin lispro efficacy  (that is, insulin dose, HbA1c) will be utilized to direct ly 
monitor for any  potenti al neutralizing effect of anti -lispro antibodi es.
Samples will  be retained for a m aximum  of [ADDRESS_563728] patient visit for the study , or 
for a shorter peri od if regulat ions and ERBs impose shorter time limits, at a facilit y selected by  
[CONTACT_47551] i ts desi gnee.  The durati on allows the sponsor to respond to future regulatory  requests 
related to LY900014.
9.9. Health Economics
The self -reported questionnaires will be administered according to the Schedule o f Activities
(Secti on 2, Table ITRO. 1.)in countries where the questionnaires have been translated into the 
native language of the regio n and linguist ically validated.
9.9.1. EQ-5D-5L
The European Qualit y of Life –5 Dimensio ns 5 Level (EQ-5D- 5L) ( vanReenen and Janssen 
[WWW] ) is a patient -rated questionnaire used to evaluate healt h status.  The questionnaire 
consists of [ADDRESS_563729] part assesses 5 dimensions (mobilit y, self -care, usual  activities, 
pain/disco mfort, and anxiet y/depressi on) that have 5 possible levels of response (no problems, 
slight problems, moderate problems, severe problems, extreme problems).   This part of the 
EQ-5D can be used to generate a healt h state index score, which is often used to compute 
qualit y-adjusted life years for utilizat ion in healt h economic analyses.  The healt h state index 
score i s calculated based on the responses to the 5 dimensio ns, providing a single value on a 
scale fro m less than 0 (where 0 is a healt h state equivalent to death; negat ive values are valued as 
worse than dead) to 1 (perfect healt h), wi th higher scores indicating better health ut ility.  The 
second part of the questionnaire consists of a visual analog scale (VAS) on which the patient 
rates thei r perceived healt h state from 0 (worst imaginable healt h state/the worst health y ou can 
imagine) to 100 (best imaginable health state/the best health you can imagine).
I8B-MC-ITRO(c)Clinical Protocol Page [ADDRESS_563730] ionnaire (ITSQ) (Anderson et al.2004) is a validated 
instrum ent con taining [ADDRESS_563731] better 
outcom es.  In addi tion to an overall score, the items that make up the 5 domains of sat isfaction 
are categori zed as:
Inconvenience o f Regimen (5 items)
Lifest yle Flexibilit y (3 items)
Glycemic Control (3 items)
Hypoglycemic Control  (5 items)
Insulin Delivery Device Sat isfaction (6 items).
All individual patient-domain scores will be calculated as the mean of nonmissing items in the 
domain if <20% of the items within the relevant domain are missing otherwise, the domain score 
will be missing.  The domain scores will be transformed to a scale of 0 -100 (derived 
as100*[7 -raw score]/6).  An overall score is calculated as the mean of the nonmissing 
transformed domain score and only calculated when all [ADDRESS_563732] ion.
I8B-MC-ITRO(c)Clinical Protocol Page [ADDRESS_563733] the hypothesis that LY900014 is noninferior to 
Hum alogon glycemic control as measured by [CONTACT_314853] m baseline to Week 16 in HbA1c in 
patients with T1D when admin istered in a double -blind m anner using CSII with bolus doses 
delivered 0 to 2 minutes prior to the meal.  
Patients will be randomized in a 1:1 ratio to double -blind LY900014 with bolus dose delivered 0 
to 2 minutes before meals ordouble -blind Hum alogwith bo lus doses delivered 0 to2 minutes 
before meals.   Assuming an NIM of 0.4%, no true difference between treatment groups , and an 
SD of 0.88%, 368completers (184 in each treatm ent group ) will provide at least 99% power to 
show noninferiorit y between LY900014 and Hum alogin change fro m baseline to Week 16 in 
HbA1c using the upper limit of a two -sided 95% confidence interval (CI) ( LY900014 –
Hum alog).  Assuming a 12% dropout rate for 16 weeks, approximately 420patients will need to 
be randomized.  This sample size also has 90% power to show noninferiorit y between LY900014
and Humal ogusing a 0.3% NIM at Week 16.  
I8B-MC-ITRO(c)Clinical Protocol Page 60
LY90001410.2. Populations for Analyses
For purposes of analysis, the following populat ions are defined:
Population Description
Entered All patient swho give informed consent
Enrolled All patient s who receive at least [ADDRESS_563734] 1 dose of the randomly assigned IP.   
Treatment group will be defined based on the treatment the patient s were assigned .
Abbreviation:  IP =investigational pr oduct.
10.3. Statistical Analyses
10.3.1. General Statistical Considerations
Statistical analysis o f this study  will be the responsibilit y of Lilly or i ts desi gnee.   Any change to 
the data analysis methods described in the protocol will require an amendment ONLY if it 
changes a principal feature of the protocol.  Any  other change to the data analysis methods 
described in the protocol, and the just ificat ion for making the change, will be described in the 
statist ical analysis plan ( SAP)or the clinical study  report (CSR).  Addit ional exploratory  
analyses o f data will be conducted, as deemed appropriate.
The primary  analysis is for the treatment period up through Week 16 .  
Efficacy analyses will be conducted on all rando mized patients according to the treatment the 
patientsareassigned . The analyses for the primary and mult iplicity-adjusted obj ectives will be 
perform ed for the efficacy  estimand incl uding data collected prior to permanent discont inuat ion 
of IP and for the ITT estimand including all data collected through Week 16 regardl ess of IP use 
(Secti on [IP_ADDRESS] ).  Unless otherwise specified, the efficacy analyses for other secondary 
objectives and explo ratory  object ives will be performed for the efficacy estimand .  When change 
from baseline is included as a response variable of analysis models , the patientwill be included 
in the analysis only if a baseline and a postbaseline measurement are available .  
Safety analyses will be conducted on the Safet y popul ation.Analyses of AEs will include [ADDRESS_563735] -treatm ent may  be conducted as needed.  Analyses of safet y laboratory  
measurements will be performed on all data collected during the planned treatment period 
regardl ess of IP use.  
Unless otherwise noted, all tests of treatment effects will be conducted at a 2 -sided alpha level 
of0.05, and CIswill be calculated at 95%, 2 -sided.  All tests o f interacti ons between treatment 
groups and other factors will be conducted at a 2- sided alpha level o f 0.10.  Coun tries in similar 
geographi c regi ons wi th fewer than 10 patients, based on the all- randomized populat ion, will be 
I8B-MC-ITRO(c)Clinical Protocol Page [ADDRESS_563736] 10 patient s.  All analyses using country  in the 
model will use a pool ed country , unless otherwise specified.  The final pooling by  [CONTACT_443223] c regi on will  be finalized pri or to data l ock.
A graphical approach for mult iple co mparisons (Bretz et al. 2011) will be used to strongly  
control  the overall Ty pe I error (2 -sided al pha l evel of 0.05) for testing the treatment effect for 
the primary  and multiplicit y adjusted object ives.  
Baseline is defined as the last nonmissing measurem ent at or before the randomizat ion visit 
(Visit 4) unless otherwise specified.  
Arestricted -maximum -likelihood -based, mixed model repeated measures (MMRM) analysis will 
be used to analyze continuous longitudinal variables.  A ll the longitudinal observati ons at each 
scheduled postbaseline visit will be included in the analysis . The m odel for th eanalysis of the 
primary  efficacy  endpoint of change from baseline in HbA1c will include the fixed class effects 
of treatm ent, strata (pooled country  and patient’s personal CGM use during the study ), visi t, and 
treatm ent-
by-visit interaction, as well as the continuous, fixed covariate of baseline value.  For
analyses o f variables other than HbA1c, the HbA1c stratum  (≤7.5%, >7.5%) will be included in
the model.  An unstructured covariance structure will be used to model the within -patienterrors.  
Significance tests will be based on least-squares ( LS) means and Ty pe III tests.  SAS PROC 
MIXED will be used to perform the analysis.  If this analysis fails to converge, the following 
covari ance structures will be tested in order:
Toeplitz with heterogeneit y
Autoregressive with heterogeneit y
Com pound symmetry  with heterogeneous variances
Toeplitz
Autoregressive
Com pound symmetry  without heterogeneous variances.
The first covariance structure that converges will be used.  The Kenward -Roger approximat ion 
will be used to estimate deno minator degrees of freedom.  
An analysis o f covari ance (ANCOVA) will also be used to analyze continuous variables
collected only  at baseline an d endpoint .  The model will include treatm ent and strata (pool ed 
country , HbA1c stratum  (≤7.5%, >7.5%), and patient ’s personal CGM use during the study ) as 
fixed effects and baseline as a covariate .  Unless otherwise stated, m issing endpo ints will be 
imputed using the last -observat ion-carried-forward (LOCF) approach, using only  postbaseline 
data.  
For continuous measures, summary statist ics will include sample size, mean, SD, median, 
minimum, and maximum for both the actual and the change fro m baselin e measurements.  
Least -square mean sand standard errors derived from the analysis models will also be displayed 
for the change fro m baseline measurements.  Treatment comparisons will be displayed showing 
I8B-MC-ITRO(c)Clinical Protocol Page 62
LY900014the treatment difference LS mean s and the 95% CIs fo r the treatment differences, along with the 
p-values for the treatment comparisons.
For categorical measures, summary  stati stics will include sample size, frequency, and 
percentages.  Fisher’s
exact test or Pearson’s chi -square test will be used for treatm ent 
comparisons.  
10.3.2. Treatment Group Comparability
[IP_ADDRESS]. Patient Disposition
A detailed description o f patientdisposi tion will be provi ded.  Frequency  counts and percentages 
of all patients entered, enrolled, rando mized, co mpleting, and/or discontinuing fro m the study  
will be presented for each treatment group.  Reasons for discont inuat ion from study  treatm ent 
and fro m the study  during the treatment period will be summarized and co mpared between 
treatm ent groups using Fisher’s exact tests .  Reasons for discont inuation from the study  during 
the lead -in and fo llow-up peri ods will  be summarized.  
[IP_ADDRESS]. Patient Characteristics
Standard baseline characterist ics of age, sex, ethnicit y, race, hei ght, wei ght, and BMI will be 
summarized for all rando mized patients.  Summary statist ics will include sample size, mean, SD, 
median, minimum ,and m aximum for continuous measures and sample size, frequency , and 
percent for categorical measures.  Comparisons between treatment groups will be performed 
using Fisher’s exact t est or Pearson’s chi -square test for categorical data and an analysis o f 
variance (ANOVA )with treatm ent in the m odel for continuous data.  Baseline diabetes 
characterist ics (including pump brand/model) will be summarized in a similar manner.  
Medical his tory and AEs at baseline will be summarized by  [CONTACT_11702]  (PT) within system  
organ class, and comparison between treatment groups will be performed using Fisher’s exact 
test.  
[IP_ADDRESS]. Concomitant Therapy 
The ty pe of rapid -acting insulin therapy , and the total , basal  and bol us insulin doses at study  
entry  and at baseline will be compared between treatment groups using Fisher’s exact tests and 
ANOVA wit h treatment in the model.  
Concomitant medicat ions used during the treatm ent peri od will be summarized and compared 
between treatment groups using Fisher’s exact test.  
10.3.3. Efficacy Analyses
[IP_ADDRESS]. Primary Analyses
The primary  object ive of this study  is totest the hypothesis that LY900014 is noninferior to 
Hum alogon glycemic control ( NIM=0.4% for HbA1c) in patients with T1D using CSII with 
bolus doses delivered 0 to 2 minutes prior to the meal for 16 weeks .  There will be 2 primary  
analysis methods, each tested at the full significance level of 0.05.  
I8B-MC-ITRO(c)Clinical Protocol Page 63
LY900014For the US FDA submission, the primary  analysis will use the copy  reference approach to impute 
missing data based on mult iple imputations with a pattern mixture model.  This analysis is for 
the ITT estimand (treatment regimen estimand) which will include a ll data collected regardless 
of IP use.  The reference for each treatment group will be fro m the retri eved dropout patients 
who discont inue IPbut have the measurement at the primary endpoint in the same treatment 
group.  If there are only a limit ed number of patients in the reference group as described above 
that leads to a failure in performing the proposed multiple imputation analysis, the reference will 
be changed to include all observed data from all rando mized pat ients in the same treatment arm 
who co mplete the study  without missing data.  After imputation, the primary efficacy 
comparison will  be based on the contrast between LY900014 and Humal ogfrom the ANCOVA 
analysis of change fro m baseline to Week [ADDRESS_563737] between LY900014 and Hum alogat Week 16 (Visit 13) f rom the MMRM analysis 
of change from baseline in HbA1c including data collected fro m all rando mized patients prior to 
perm anent discont inuat ion of IP through Week 16 (efficacy  estimand). The analysis model and
select ion of covariance structure is described in Section 10.3.1 .  
For both primary  analysis approaches, LY900014 will be declared noninferior to Humalog if the 
upper limit of the 2
-sided 95% CI for the LS mean difference in the change from baseline in 
HbA1c for LY900014 minus Humal ogis below +0.4%.  In addit ion, the 95% CI for the 
treatm ent difference will be compared to an alternative NIM of +0. 3%.  Both estimands will be 
tested at the full significance level of 0.05.  
In addit ion to the primary  object ive, the superiority o f LY900014 in controlling HbA1c 
compared withHumal ogwill also be assessed for each analysis approach described above.  If the 
p-value is less than the alpha level from the graphical approach allo cated to the superiorit y 
hypothesis, LY900014 will be declared superior to Humalog .
[IP_ADDRESS].1. Sensitivity Analyses for Missing Data
Amissing -
not-at-random -based analysis will be performed for both the efficacy and ITT 
estimands to assess sensit ivity to departures fro m the missing -at-random (MAR) assumption . 
The ti ppi[INVESTIGATOR_007] -point approach that will be used is similar to a progressive stress test (Ratitch et al.
2013).   The basic idea is to impu te the missing values and add a value (delta) to the imputed 
values of the experimental treatm ent group and perform an analysis for the primary endpo inton 
the del ta-adjusted data set to see whether the conclusion of the primary analysis is overturned.  If
not, a larger del ta is chosen ,and the process repeated until the primary  resul t is overturned.  If 
the del ta requi red to overturn the primary  resul t is not a plausible departure from MAR, then the 
primary  resul t is robust to plausible departures from MAR .  The init ial delta is set to 0.1 with an
increment of 0.1.  Imputati on under t he noninferiorit y null method ( where delta equals the NIM )
will be included as a special case of the progressive stress test.
For the ITT estimand, the reference group will be as described for the FDA primary  analysis, and 
ANCOVA on the change fro m baseline to Week 16 in HbA1c will be used.  
I8B-MC-ITRO(c)Clinical Protocol Page 64
LY900014For the efficacy estimand, the reference group will be the Hum alogtreatm ent group.  Im putati on 
will be for all lo ngitudinal visits. 
[IP_ADDRESS]. Seco ndary Analyses
A graphical approach for mult iple co mpar isons will be used to strongly control the overall 
TypeI error (2 -sided al pha l evel of 0.05) for testing the treatment effect for the primary and the 
following mult iplicity adjusted object ives:  superio rity of LY900014 compared wi th Hum alog
for 1-hour PPG during MMTT at Week 16 , 2-hour PPG during MMTT at Week 16, change from 
baseline to Week 16 in HbA1c , 
the duration of t ime glucose values are within target range during 
a 24-hour period at Week 16 ,and the duration of t ime glucose values are within target range 
during day time (0600 hours to midnight) at Week 16. The gluco se target range isdefined as 70
to180mg/dL (3.9 to 10.0 mmo l/L), both inclusive , obtained fro m CGM ..  Analyses will be 
perform ed for both the efficacy estimand and ITT estimand as described in Sect ion [IP_ADDRESS]
using the same graphical testing scheme .
The graphical testing scheme will be described in the SAP.  The study total alpha level (or 
study -wise ty pe I error) i s preset to be 5% for each estim and. The study  total  alpha level  will be 
used for the primary  objective in the init ial step. The alpha level will be allocated to other key  
endpo ints based on the weights in testing paths once the primary  endpoint i s successfully  
demonstrated. If [ADDRESS_563738] procedure continues unt il none of the remaining 
hypotheses can be demonstrated with their preserved alphas or all hypotheses are demonstrated 
successful.   
An ANCOVA model as described in Section 10.3.1 will be used to analyze the 1 -hour and 
2-hour PPG. However, if the percentage of the patients with missing MMTT data at baseline is 
higher than 15%, a constrained longitudinal data analysis model (Liu et al. 2009; Lu 2010) will 
be used instead.  Analys is details will be documented in the SAP.
For continuous longitudinal secondary  endpoints, the MMRM model similar to that for the
primary  analysis will be used with HbA1c stratum (≤7.5%, >7.5%) added as a fixed effect .  
Durati on and percent time in range , time in hypoglycemia and time in hyperglycemia derived 
from CGM data will also be analyzed using MMRM model with HbA1c stratum  
(≤7.5%, >7.5%) 
as a fixed effect .  Conti nuous nonlo ngitudinal secondary endpoints will be analyzed using the 
ANCOVA model with treatment and strata as fixed effects and baseline as a covariate.   
Treatment comparisons for the proportion of patients with HbA1c <7.0% and ≤6.5% will be 
analyzed using a lo ngitudinal logist ic regressio n with repeated m easurements conducted by  a 
generalized linear mixed model including independent variables of treatment, baseline HbA1c 
value, visit, baseline HbA1c by  [CONTACT_176260], and treatm ent-by-visit interaction.  Actual  and 
change from baseline in basal, bo lus, and total dose, as well as the bolus /total insulin dose ratio 
will be analyzed by [CONTACT_443224] 10.3.1 .
[IP_ADDRESS]. Tertiary/Exploratory Analyses
Continuous variables and the change from baseline for these variables will be analyzed by [CONTACT_5640] 
I8B-MC-ITRO(c)Clinical Protocol Page 65
LY900014MMRM or ANCOVA models described in Section 10.3.1. Categorical variables will be 
analyzed either by [CONTACT_443225] ( for example, logistic regressio n) or by  [CONTACT_3493]’s exact test or 
Pearson’s chi -square test.  Analysis details for the tertiary  endpoints will  be described in the 
SAP.
10.3.4. Safety Analyses
Safety measures w ill include AEs, hypoglycemia, unplanned infusio n set changes and reasons , 
vital signs and wei ght, treatm ent exposure, l aboratory  measures, and ant ibodies to insulin lispro.  
Events that are newly  reported after the first dose of IP or reported to worsen in severit y from 
baseline will be considered TEAEs.  The Medical Dict ionary for Regulatory  Activities 
(MedDRA )
lowest level term (LLT) will be used in the treatment -emergent assessment.  The 
maximum severit y for each LLT during the baseline period will be used as baseline severit y.
SAEs, AEs reported as reason for discont inuat ion from  the IPor study , and TEAEs will be 
summarized in tables using the MedDRA PT, sorted by  [CONTACT_362308]900014 treatm ent group.  TEAEs will also be summarized by [CONTACT_443226] y.  For events that are specific to 
only one sex, the denominator and computation of the percentage will include only patients from 
the given sex.  The number and proporti on of  patients with at least 1event for each ty pe of event 
will be summarized and co mpared between treatment groups using Fisher’s exact test.   Serious 
adverse events , AEs reported as reason for discont inuat ion from the study , and TEAEs willbe 
summarized for open -label Humal ogduring the l ead-in period .  
Hypoglycemia rates will be summarized for periods of 1 y earand 100 y ears (severe 
hypoglycemia only ).  The rate of severe hypoglycemia per 100 y ears will be com pared between 
treatm ent groups using the empi[INVESTIGATOR_362263] (details will be described in the SAP).  F or each of 
other categories of hypoglycemia, the number of hypoglycemia events during a specific period 
(rate) after randomizat ion (for example , 0to 4 weeks of treatment period) will be analyzed b y 
using a negat ive bino mial regressio n modelincluding treatment .  An offset defined as the log 
transformation of treatment exposure in the specific period (day s)/365.[ADDRESS_563739] 1 hypoglycemic event in each category (incidence) during a specific period after 
rando mizat ion will be analyzed using a logist ic regressio n model including treatm ent.  
Similarly, a negat ive binomial model and a logistic regression model including treatment will be 
used to analyze the rate of pump occlusio n alarms leading to unplanned infusio n set changes per 
[ADDRESS_563740] 1 occlusion alarm (incidence) leading to 
unplanned infusio n set changes , respect ively.
Continuous safety  variables, as well as the change fro m baseline for these variables, will be 
analyzed by [CONTACT_443227].  For categorical variables , Fisher’s exact test 
or Pearson’s chi -square test will be used t o compare treatment groups unless otherwise specified.  
The analyses for assessing immunogenicit y data will be described in the SAP after being agreed 
with the FDA on the threshold for determining treatment- emergent antibodi es to insulin lispro.
I8B-MC-ITRO(c)Clinical Protocol Page 66
LY90001410.3.5. Other Ana lyses
[IP_ADDRESS]. Health Economic s
Summary  statistics, including number of patients and proportion of categorical outcomes 
(5levels) for the 5 dimensio ns (mo bility, self -care, usual  activity, pain/discomfort ,and 
anxiet y/depressi on) of the EQ -5D- 5L will be provided by [CONTACT_443228].  The change 
from baseline to LOCF endpo int (Week 16, Visit 13) in the EQ - 5D- 5L [LOCATION_006] populat ion-based 
healt h state index score and EQ -VAS score will be analyzed using the ANCOVA model 
described in the Section 10.3.1 .
For the ITSQ, the change from baseline to LOCF endpo int while on treatment in each domain 
transformed score (inconvenience, lifest yle, hypogly cemic control , glycemic control , and 
delivery  system ) and overall transformed score will be analyzed using the ANCOVA model 
described the Section 10.3.1 .
[IP_ADDRESS]. Subgroup Analyses
The fo llowing subgroups will be analyzed using the efficacy  estimand to evaluate consistency  of 
treatm ent effects on the primary  efficacy  measure if there are sufficient numbers of patients in 
each treatment by  [CONTACT_6496] (for example ,10%) :
Age (40 years, 40 years)
HbA1c stratum  (≤7.5%, >7.5%)
Patient’s personal CGM use during the study  (yes/no)
Patient’s use of low glucose suspends during the study  (yes/no)
Sex (Male or Female)
BMI (<25, ≥25 kg/m2)
Bolus delivery  speed at study  entry
Durati on of  Diabetes ( using the median as the cutoff )
Race
Ethnicit y
Country
Region
Analyses for HbA1c and change from baseline in HbA1c will be performed using an MMRM 
model that includes the sam e fixed effects given for the primary  analysis model p lus factors of 
subgroup, 2-way interacti on of  subgroup and treatment, 2-way interacti on of  subgroup and visit, 
and 3-way interact ion of treatment, visit and subgroup.  The interaction of subgroup and 
treatm ent at the primary  endpoint (Week 16) will be evaluated to assess the treatment by 
[CONTACT_226418].  When analyzing HbA1c stratum ( ≤7.5%, >7.5%) as a subgroup the 
baseline HbA1c will be not be included as a covariate to avoid confounding .  
I8B-MC-ITRO(c)Clinical Protocol Page 67
LY900014Addit ional subgroup analyses may  also be performed.
10.3.6. Interim Analyses
No interim analyses are planned for this study .  If an unplanned interim analysis is deemed 
necessary , the appropri ate Lilly medical director, or designee, will be consulted to determine 
whether it is necessary to amend the protocol.
I8B-MC-ITRO(c)Clinical Protocol Page [ADDRESS_563741] ionnaire. Clin Ther . 
2004;26(4):[ADDRESS_563742] D, Saboo B, Schatz D, Stoner K, Urakami T, 
Weinzimer SA, Phillip M . Clinical targets for continuous glucose monitoring data 
interpretati on: Reco mmendations from the Internatio nal Consensus on Time in Range
[published online June 8, 2019] . 
Diabetes Care . doi: 10.2337/dci19-0028.
Bretz F, Posch M, Glimm E, Klinglmueller F, Maurer W, Rohmeyer K. Graphical approaches for 
multiple comparison procedures using weighted Bonferroni, Simes, or parame tric tests. 
Biom J. 2011;53(6):894 –913.
[CCNYHA] The Criteria Co mmit tee of  the [LOCATION_001] Heart Associat ion. Nom enclature and 
criteria for di agnosis of diseases of the heart and great vessels. 9th ed. [LOCATION_011] (MA): Little, 
Brown & Company; 1994: 253-256.
Fineberg NS, Fineberg SE, Anderson JH, Birkett MA, Gibson RG, Hufferd S. Immuno logic 
effects of insulin lispro [Ly s (B28), Pro (B29) human insulin] in IDDM and NIDDM pat ients 
previously treated with insulin. Diabetes . 1996;45(12):[ADDRESS_563743] ion of antibody  response in pati ents wi th type 1 or ty pe 2 di abetes. 
Diabetes Care . 2003;26(1):89 -
96.
Hum alog [package insert]. Indi anapo lis, IN: Eli Lilly  and Com pany; 2015.
Hum alog [summary of product characteristics]. The Netherlands . Eli Lilly Nederland B.V ; 2016
Liu GF, Lu K, Mogg R, Mallick M, Mehrotra D V.  Should baseline be a covariate or dependent 
variable in analyses of change fro m baseline in clinical trials? Statist Med. 
2009;28 (2):2509 -2530.
Lu K. On efficiency  of constrained l ongitudinal  data analysis versus longitudinal analysis of 
covari ance. Biometrics . 
2010; 66(3):891 -896.
Ratitch B, O’Kelly M, Tosiello R. Missing data in clinical trials: fro m clinical assumpt ions to 
statist ical analysis using pattern mixture models. Pharm Stat . 2013;12(6):337 -
347.
Remodulin [prescribing informat ion]. Research Triangle Park, NC: United Therapeutics Corp; 
2014.
Van Reenen M ,Janssen B. EuroQol Research Foundat ion. EQ -5D- 5L Users Guide.EuroQol.org. 
Available at :
http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Fo lders_Flyers/EQ -5D- 5L_
UserGuide_2015.pdf . Accessed December 9, 2015.
I8B-MC-ITRO(c)Clinical Protocol Page 69
LY90001412. Appendices
I8B-MC-ITRO(c)Clinical Protocol Page 70
LY900014Appendix 1. Abbreviations and Definitions
Term Definition
1,5-AG 1,5-Anhydroglucitol
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
patient administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment .  An adverse event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporal ly associated with the use of a medicinal (investigational) product, whether or not 
related to the medicinal (investigational) product.
AIT active insulin time
ALP alkaline phosphatase
ALT alanine aminotransferase
ANCOVA analy sis of covariance
ANOVA analy sis of variance
AST aspartate aminotransferase
BG blood glucose
blinding/masking A single -blind study is one in which the investigator and/or his staff are aware of the 
treatment but the patient is not, or vice versa, or when the sponsor is aware o f the treatment ,
but the investigator and/his staff and the patient are not.
A double -blind study is one in which neither the patient nor any of the investigator or 
sponsor staff who are involved in the treatment or clinical evaluation of the patients are 
aware of the treatment received.
BMI body mass index
CF correction factor
CGM continuous glucose monitoring
CI confidence interval
CRF case report form
Product complaint Product complaints are a customer’s written, electronic, or oral communication that alleges 
deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or 
performance of a Lilly product after it is released for distribution.
CR Carbohydrate ratio
I8B-MC-ITRO(c)Clinical Protocol Page 71
LY900014CRP/CRS clinical research physician: Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, clinical research scientist, 
global safety physician, or other medical officer.
CSII continuous subcutaneous insulin infusion
CSR clinical study report
ECG electrocardiogram
EDC electronic data -capture
eCRF electronic case report form
eGFR estimated glomerular filtration rate
enroll The act of assigning a patient to a treatment.  Patients who are enrolled in the trial are those 
who have been assigned to a treatment.
enter Patients entered into a trial are those who sign the informed consent form directly or through 
their legally acceptable representatives.
EQ-5D-5L European Quality of Life –[ADDRESS_563744]
FBG fasting blood glucose 
FDA Food and Drug Administration
FGM flash glucose monitoring
GCP good clinical practice
GD glucodynamic(s)
GRAS Generally Recognized As Safe
HbA1c hemoglobin A1c
HCP health care provider
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonisation of Technical Requirements for Pharmaceuticals for 
Human Use
I8B-MC-ITRO(c)Clinical Protocol Page [ADDRESS_563745]: A pharmaceutical form of an active ingredient or placebo being 
tested or used as a reference in a clinical trial, including products already on the market when 
used or assembled (formulated or packaged) in a way different from the authorized form, or 
mark eted products used for an unauthorized indication, or marketed products used to gain 
further information about the authorized form.
ISF Insulin sensitivity factor
ITSQ Insulin Treatment Satisfaction Questionnaire
ITT intention to treat:  The principle that asserts that the effect of a treatment policy can be best 
assessed by [CONTACT_41445] a patient (that is, the planned 
treatment regimen) rather than the actual treatment given.  It has the consequence that patients 
allocated to a treatment group should be followed up, assessed, and analyzed as members of 
that group irrespective of their compliance to the planned course of treatment.
IV intravenous
IWRS interactive web -response sy stem
LLT lowest level term
LOCF lastobservation carried forward
LS least squares
MAR missing at random
MDI multiple daily injections
MedDRA Medical Dictionary for Regulatory Activities
MMRM mixed-effect model repeated measure
MMTT Mixed -meal tolerance test
NIM noninferio rity margin
NPH neutral protamine Hagedorn
PD Pharmacodynamic(s)
PK pharmacokinetic(s)
PPG postprandial glucose
PT preferred term
I8B-MC-ITRO(c)Clinical Protocol Page [ADDRESS_563746] deviation
SMBG self-monitored blood glucose
S[LOCATION_003]Rs suspected unexpected serious adverse reactions
T1D type 1 diabetes
T2D type 2 diabetes
TBL total bilirubin level
TEAE treatment -emergent adverse event:  An untoward medical occurrence that emerges during a 
defined treatment period, having been absent pretreatment, or worsens relative to the 
pretreatment state, which and does not necessarily have to have a causal relationship with this 
treatment.
ULN upper limit of normal
Unexplained
HyperglycemiaHigh blood glucose (≥300 mg/dL) that cannot be explained by a missed prior bolus, dietary 
indiscretion, rebound or treatment of hypoglycemia, a pump failure, an empty pump 
reservoir, an infusion
set complication ( e.g.; kinked, came out, leaking), or an infusion site complication
(e.g.; pain, redness).
VAS visual analog scale
I8B-MC-ITRO(c)Clinical Protocol Page 74
LY900014Appendix 2. Clinical Laboratory  Tests 
Clinical Laboratory Tests a
Hematology Clinical Chemistry( Serum Concentrations of):
Hemoglobin Sodium
Hematocrit Potassium
Erythrocy te count (RBC) Total bilirubin
Mean cell volume Direct bilirubin
Mean cell hemoglobin concentration Alkaline phosphatase
Leukocytes (WBC) Alanine aminotransferase (ALT)
Neutrophils, segmented Aspartate aminotransferase (AST)
Lymphocy tes Blood urea nitrogen (BUN)
Monocytes Creatinine
Eosinophils Uric acid
Basophils Calcium
Platelets Chloride
Magnesium
Urinalysis Total protein
Specific gravity Glucose
pH Albumin
Protein Creatine kinase (CK)
Glucose eGFR (calculated by [CONTACT_443229]) b
Ketones
Blood 1,[ADDRESS_563747] (females only) c
Follicle -stimulating hormone d
Abbreviations:  eGFR = estimated glomerular filtration rate ; HbA1c =glycated hemoglobin A1c IP=investigational 
product; MDRD =Modification of Diet in Renal Disease Study; RBC =red blood cells; WBC =white blood 
cells.
aAll laboratory tests will be assayed by a Lilly -designated central laboratory, unless otherwise noted.
bMDRD:  175 [SCr] 1.154 [age] –0.203 [0.742 if female] [1.212 if black]; SCr =serum creatinine 
(mg/dL), final value will be expressed as mL/min/1.[ADDRESS_563748] within 24 hours prior to IP exposure at randomization and at other times at the investigator’s 
discretio n.  W hen required per local regulations and/or institutional guidelines, local pregnancy testing will occur 
at mandatory times during the stud y treatment period.  
dFollicle -stimulating hormone test must be performed at Visit 1 for a postmenopausal woman who is between 
50and 54 years of age (inclusive) with an intact uterus, not on hormone therapy, and who has had at least 
6months of spontane ous amenorrhea.
I8B-MC-ITRO(c)Clinical Protocol Page 75
LY900014Appendix 3. Study  Governance Considerations
I8B-MC-ITRO(c)Clinical Protocol Page [ADDRESS_563749] igator is responsible for ensuring:
that the patientunderstands the potential risks and benefits of part icipating in 
the study
that informed consent is given by [CONTACT_57996].  This 
includes obtaining the appropriate signatures and dates on the informed 
consent form (ICF) prior to th e performance of any protocol procedures and 
prior to the administration o f investigational product (IP).
answering any quest ions the patientmay have throughout the study  and 
sharing in a t imely manner any  new informat ion that m ay be relevant to the 
patient’s willingness to continue his or her participation in the trial.
Appendix 3.1.2. Ethical Review
The invest igator or an appropriate local representative must give assurance that the ethical 
review board (ERB )was properly constituted and convened as requ ired by [CONTACT_443230](ICH) 
guidelines and other applicable laws and regulations.
Docum entati on of  ERB approval  of the protocol and the informed consent form (ICF) must be 
provi ded to Lilly  before the study  may begin at the invest igative site(s).  Lilly or its 
representatives must approve the ICF, including any changes made by [CONTACT_41429], before it is used 
at the investigative site(s).  All ICFs must be compliant with the ICH gui deline on good clinical 
practi ce(GCP ).
The study  site’s ERB(s) shoul d be provided wi th the f ollowing:
the current Invest igator’s Brochure (IB)and updates during the course of the 
study
ICF
relevant curri cula vi tae.
Appendix 3.1.3. Regulatory Considerations
This study  will be conducted in accordance wit h:
consensus ethics principles derived fro m internat ional ethics guidelines, including 
the Decl aration of Helsinki and Council forInternational Organizati onsof
Medical Sciences (CIOMS ) Internat ional Ethi cal Gui delines
applicable ICH GCP Guidelines
applicable laws and regulations
I8B-MC-ITRO(c)Clinical Protocol Page [ADDRESS_563750] -party .
Appendix 3.1.4. Investigator Information
A physician wit h exper tisetreating patients with type1 diabetes ( T1D)and experience in clinical 
trials.
Appendix 3.1.5. Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately  describes the planned design and conduct of the 
study .
After reading the protocol, each principal invest igator will sign the protocol signature [CONTACT_25327] a copy  of the signed page to a Lilly representative.
Appendix 3.1.6. Final Report Signature
[CONTACT_314867] (CSR )coordinating investigator [INVESTIGATOR_81087] , 
indicat ing agreement that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study .
An invest igator will be selected by [CONTACT_443231] y study  team  to serve as the CSR coordinating 
Invest igator. The sponsor’s responsible medical officer and statistician will approve the final 
CSR for thi s study , confi rming that, to the best of his or her knowledge, the report accurately 
describes the con duct and results of the study .
Appendix 3.2. Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provi de instructi onal materi al to the study  sites, as appropriate
sponsor start -up training to instruct the invest igators and study  coordinators.  This 
training will give instruction on the protocol, the complet ion of the CRFs, and 
study  procedures
make periodic visit s to the study  site
be available for consultation and stay  in contact w ith the study site personnel by 
[CONTACT_2319], tel ephone, and/or fax
review and evaluate CRF data and use standard computer edits to detect errors in 
data collect ion
conduct a qualit y review of the database
In addit ion, Lilly or its representatives will periodicall y check a sample of the patientdata 
recorded against source documents at the study  site.  The study  may be audi ted by  [CONTACT_47551] i ts 
representatives, and/or regulatory  agencies at any  time.  Invest igators will be given notice before 
an audit occurs.
I8B-MC-ITRO(c)Clinical Protocol Page [ADDRESS_563751] igator is responsible for ensuring the accuracy, completeness, legibilit y, and timeliness 
of the data reported to the sponsor.
An electronic data -capture (EDC) sy stem  will be used in this study  for the collect ion of CRF 
data.  The investigator maintains a separate source for the data entered by  [CONTACT_32864] -provided EDC system.  The invest igator is responsible for the 
ident ificat ion of any data to be considered source and for the confirmat ion that data reported are 
accurate and complete by  [CONTACT_11003].
Addit ionally , clinical  outcom e assessment data (questionnaires and self -reported di ary data) will 
be co llected by [CONTACT_423], via a paper sou rce document and will be transcribed by [CONTACT_1275] -site personnel into the EDC system.
Data collected via the sponsor- provided data capture system will be stored with a third party.  
The invest igator will have cont inuous access to the data during the study  and unt il 
decommissio ning of the data -capture system.  Prior to decommissio ning, the invest igator will 
receive an archival copy  of pertinent data for retention.
Data m anaged by  a central  vendor, such as laboratory  test data, will be stored electroni cally  in 
the central  vendor’s database system and reports will be provided to the investigator for review 
and retention.  Data will subsequent ly be transferred fro m the central  vendor to the Lilly  data 
warehouse.
Data from co mplaint forms submitted to Lilly will  be encoded and stored in the global product 
complaint m anagement sy stem .
Appendix 3.3. Study and Site Closure
Appendix 3.3.1. Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly , the invest igator, or the ERB of the s tudy 
sitejudges it necessary for medical, safety , regul atory , or other reasons consistent with 
applicable laws, regulat ions, and GCP.
Appendix 3.3.2. Discontinuation of the Study
The study  will be di scontinued if Lilly judges it necessary for medical, saf ety, regul atory , or 
other reasons consistent with applicable laws, regulat ions, and GCP.
I8B-MC-ITRO(c)Clinical Protocol Page [ADDRESS_563752]
GGT Alkaline Phosphatase Isoenzymes a
CPK
Anti -smooth muscle antibody (or anti -actin antibody) a
Abbreviations:  ALT =alanine aminotransferase; AST =aspi[INVESTIGATOR_82355]; CPK =creatinine 
phosphokinase; GGT =gamma -glutamyl transferase; Ig =immunoglobulin; INR =internatio nal no rmalised 
ratio; RBC =red blood cells; WBC =white blood cells.
aAssay ed by [CONTACT_11007] -designated or local laboratory (if test results are required urgently to manage patient care) .
bReflex/confirmation dependent on regulatory requirements and/or testing availability .
I8B-MC-ITRO(c)Clinical Protocol Page [ADDRESS_563753] ive methods of contraception.  The patient may choose to use a 
doubl e-barrier method of contracep tion (see chart below ).  
Barri er protecti on m ethods wi thout concomi tant use of a spermicide are not an effect ive 
or acceptable method of contraception.  It should be noted, however, that the use of male 
and female condoms as a double -barrier method i s not considered acceptable due to the 
high failure rate when these barrier methods are combined .
Methods of Contraception
Highly Effective Methods of Contraception Effective Methods of Contraception
(Must Use Combination of 2 Methods )
Combined oral contraceptive pi[INVESTIGATOR_81061] -pi[INVESTIGATOR_4382]
NuvaRing®
Implantable contraceptives
Injectable contraceptives (such as Depo -Provera ®)
Intrauterine device (such as Mirena ®and ParaGard ®)
Contraceptive patch –ONLY women <198 lbor 90 kg
Bilateral tubal occlusion
Total abstinence a
Vasectomy Male condom with spermicide
Female condom with spermicide
Diaphragm with spermicide
Cervical sponge with spermicide
Cervical cap with spermicide
aTotal abstinence (as patient’s preferred and usual lifestyle) or in a same -sex relationship (as part of patient’s 
preferred and usual lifestyle). Periodic abstinence ( e.g., calendar, ovulation, symptothermal, post -ovulation 
methods), declaration of abstinence just for the duration of a trial, and withdrawal are not acceptable method s of 
contraception .
I8B-MC-ITRO(c)Clinical Protocol Page 81
LY900014Appendix 6. Protocol A mendment I8B-MC-ITRO (c) 
Summary
A Prospective, Randomized, Double -Blind Comparison 
of LY900014 to Humalog in A dults with Ty pe 1 Diabetes 
Using Continuous Subcutaneous Insulin Infusion
PRONTO -Pump -2
Overview
Protocol  I8B-MC-ITRO A Prospective, Randomized, Double -Blind Comparison of 
LY900014 to Humalog in Adults with Type 1 Diabetes Using Continuous Subcutaneous 
Insulin Infusion PRONTO -Pump -2 has been amended.  The new proto col is indicated by  
[CONTACT_61504] (c ) and will be used to conduct the study  in place of any preceding version o f the 
protocol .
The overall changes and rationale for the changes made to this protocol are described in the 
following table:
Amendment Summary for Protocol I8B-MC-ITRO Amendment ( c)
Section # and Name [CONTACT_19523] 1, Synopsis
Section 4, 
Objectives and 
EndpointsThe secondary objectives of [ADDRESS_563754] prandial 
glucose. 
The secondary objective that compared 
glucose time in range (70-
180 mg/dL)  
during the 24 -hour period for LY90 0014 and 
Humalog is now controlled for Type I error 
and included with the multiplicity adjusted 
objectives. 
The glucose time in range (70 -180 mg/dL) 
during the daytime period (6 am to midnight) 
for LY900014 and Humalog was added and 
is controlled for Type I error and included 
with the multiplicity adjusted objectives . PPG excursion endpoints were changed 
to actual PPG measurements based on 
improvemen ts in both fa sting and 
postprandial glucose observed in Study 
I8B-MC -ITSI and predicted in PK/PD 
models with administration of 
LY900014 by [CONTACT_213429] .  The use of absolute 
1-and [ADDRESS_563755] 
differences between treatment groups in 
this study . 
Section 9.1.2, 
Secondary Efficacy 
Assessments‘Excursions ’and ‘minus fastings serum 
glucose ’ wereremoved from the secondary 
efficacy measure of ‘Fasting and PPG 
collected during the MMTT’ to reflect the 
change in objectives. 
Section [IP_ADDRESS], 
Secondary Analyses‘Excursion’ was removed from the [ADDRESS_563756] the 
change in objectives . 
I8B-MC-ITRO(c)Clinical Protocol Page 82
LY900014Also, the duration of time glucose values w as
within the target range of 70 and 180 mg/dL
during the daytime (6 am to midnight) and 
24-hour period was added  the secondary 
analy ses. Time in range endpoints were added as 
this measure is becoming of increasing 
importance to patients and prescribers, 
as evidenced in recent consensus 
statements from ADA (Battelino et al., 
2019).  All patients in the study will 
undergo several blinded CGM 
evaluation periods; these data will form 
the basis for the TIR an alyses.  
Measurements were added to evaluate 
time in range over a 24
-hour time period 
and also over the daytime period (6 am 
to midnight).  Including these measures 
in the graphical approach allows us to 
control the type I error and correct for 
multiplicit y, meaning that these 
endpoints, if positive, may be suitable 
for inclusion in product labeling.  
I8B-MC-ITRO(c)Clinical Protocol Page 83
LY900014Revised Protocol Sections
Note: Deletions have been ident ified by [CONTACT_58001] .
Addit ions have been identified by  [CONTACT_58002] .
Section 1 Synopsis and Section 4 Objectives and Endpoints
Objective(s)/Endpoints:
Objectives Endpoints
Primary Objective
1.To test the hypothesis that LY900014 is 
noninferio r to Humalog on glycemic 
control ([NIM =0.4% for HbA1c) in 
patients with T1D using CSII for [ADDRESS_563757] the hypothesis that LY900014 is 
superior to Humalog in controlling 1-hour 
postprandial glucose (PPG) excursions2.Difference between LY900014 and Humalog in
change from baseline to Week 16 in the 1 -hour 
PPG excursion (serum glucose measured [ADDRESS_563758] ing serum 
glucose ) from a MMTT at Week 16and change 
from baseline to Week [ADDRESS_563759] the hypothesis that LY900014 is 
superior to Humalog in controlling 2-hour 
PPG excursions 3.Difference between LY900014 and Humalog in 
change from baseline to Week 16 in the 2 -hour 
PPG excursion (serum glucose measured 2 
hoursafter the start of the meal minus fasting 
serum glucose ) from a MMTT at Week 16and 
change from baseline to Week [ADDRESS_563760] the hypothesis that LY900014 is 
superior to Humalog on improving glycemic 
control (HbA1 c) 4.Difference between LY900014 and Humalog in 
change from baseline to Week [ADDRESS_563761] the hypothesis that LY900014 is 
superior to Humalog in the duratio n of time 
glucose values within target range 70 to
180mg/dL (3.9 to10.0 mmol/L), obtained 
from CGM use during 24-hour period5.Duration (in minutes and percentage of time )
with glucose values between 70 and 180 mg/dL 
(3.9 and 10.0 mmol/L), both inclusive, 
normalized to a 24- hour period, from each 
14-day  CGM session at Week [ADDRESS_563762] the hypothesis that LY900014 is 
superior to Humalog in the duration of time 
glucose values within target range 70 to
180mg/dL (3.9 to10.0 mmol/L), obtained 
from CGM use during daytime6.Duration (in minutes and percentag e of time )
with glucose values between 70 and 180 mg/dL 
(3.9 and 10.0 mmol/L), both inclusive, 
normalized to daytime  (0600 hours to 
midnight), from each 14-day CGM session at 
Week [ADDRESS_563763] to the rate of severe hypoglycemic 
events7.Rate (events/ patient /100 years) of severe 
hypoglycemic events from baseline through 
Week 16
I8B-MC-ITRO(c)Clinical Protocol Page [ADDRESS_563764] to the rate and incidence of 
documented postmeal hypoglycemia 8.Rate (events/ patient /year) and incidence 
(percen tof patients with at least 1event) of 
documented post meal hypoglycemia within 
1and 2hoursafter the start of themeal from 
baseline through Week [ADDRESS_563765] to the rate an d incidence of 
documented hypoglycemia9.Rate (events/ patient /year) and incidence 
(percent ageof patients with events) of 
documented hypoglycemic events from baseline 
through Week [ADDRESS_563766] to total, basal, and bolus insulin dose12.Change f rombaseline in bolus/total insulin dose 
ratio at Week [ADDRESS_563767] to the proportion of patient s 
achieving HbA1c targets13.The proportion of patients with HbA1c <7% 
and ≤6.5% at Week [ADDRESS_563768] to the duration of time glucose values 
are within target range (70 and 180 mg/dL 
[3.9 and 10.0 mmol/L]), obtained from CGM 
useDuration (in minutes) and percentage of time 
with glucose values between 70 and 180 mg/dL 
(3.9 and 10.0 mmol/L), both in clusive, 
normalized to a [ADDRESS_563769] to the duration of time spent in 
hypoglycemic glucose ranges, obtained from 
CGM use14.Duration (in minutes) and percentage of time 
with glucose values <54 and <70mg/dL ( 3.0 
and3.9 mmol/L), normalized to a 24-hour 
period and number of epi[INVESTIGATOR_1841], defined as at 
least 10 consecutive minutes <5 4 and
<70mg/dL, from each [ADDRESS_563770] to the duration of time spent in 
hyperglycemic glucose ranges, obtained from 
CGM use15.Duration (in minutes) and percentage of time 
with glucose values >180 and >250 mg/dL 
(10.0 and13.9 mmol/L), normalized to a 
24-hour period and number of epi [INVESTIGATOR_1841], defined 
as at least 10 consecutive minutes >18
0 and
>250 mg/dL, from each [ADDRESS_563771] to the incidence and rate of pump 
occlusion alarms that lead to an unplanned 
infusion set change16.Rate (events/ patient /30 days) and incidence 
(percent of patients with at least 1event) of 
pump occlusion alarms that lead to an 
unplanned infusion set change from baseline 
through Week [ADDRESS_563772] to the incidence and rate of 
epi[INVESTIGATOR_443176]17.Rate (events/ patient /30 days) and incidence 
(percent of patients with at least 1event of 
unexplained hyperglycemia > 300 mg/dL 
confirmed by [CONTACT_443193] 16
I8B-MC-ITRO(c)Clinical Protocol Page 85
LY900014Abbreviations:  1,5-AG =1,5-Anhydroglucitol; AIT =active insulin time; AUC =area under the curve ;
CGM =continuous glucose monitoring; CR =carbohydrate ratio; CSII =continuous subcutaneous insulin 
infusion; CV=coefficient of variation; EQ-5D-5L = EuroQol 5D -5L; EQ -VAS =EQ visual analog scale; 
HbA1c =hemoglobin A1c; HBGI =high blood glucose index; ISF=insulin sensitivity factor; ITSQ =Insulin 
Treatment Satisfac tion Questionnaire; LBGI =low blood glucose index ; MMTT =mixed meal tolerance test; 
NIM =noninferiority margin; SMBG =self-monitored blood glucose; T1D =type 1 diabetes; [LOCATION_006]=United 
Kingdom .
Section 9.1.2 Secondary Efficacy A ssessments
Fasting and PPG collected during the MMTT:
o1-hour and 2 -hour PPG excursio ns:  serum  glucose measured [ADDRESS_563773] ing serum glucose
oIncremental  areas under the serum glucose concentrati on-time curve 
from 0 to 30 minutes, 0 to 1 hour, 0 to 2 hours, 0 to 3 hours, and 0 to 
4hours after a meal; maximum serum  glucose after a m eal
oGlucose vari ability measured by [CONTACT_443214](SD)
1,5-Anhydroglucito l (1,5-AG)
SMBG 10 -point profiles:
o1-hour and 2 -hour PPG and PPG excursio ns by [CONTACT_443215]-and between -day gl ucose variabilit y measured by [CONTACT_443216]
CGM
oDurati on and percentage of time in range ( 70-180 mg/dL [ 3.9-
10.0 mmo l/L]
)during the day time (0600 hours to midnight) and 24 -
hour peri od obtained by  [CONTACT_3449] -provi ded Dexco m blinded CGM
oDurati on and percentage of time with glucose values <54 and 
<70mg/dL ( 3.0and 3.9 mmo l/L)
Section [IP_ADDRESS] Secondary Analyses
Secondary Analyses
A graphical approach for mult iple co mpar isons will be used to strongly control the overall 
TypeI error (2 -sided al pha l evel of 0.05) for testing the treatment effect for the primary and the 
following mult iplicity adjusted object ives:  superio rity of LY900 014compared wi th Hum alog
for 1-hour PPG excursion during MMTT at Week 16, 2-hour PPG excursion during MMTT at 
Week 16, and change fro m baseline to Week 16 in HbA1c , the durati on of  time gl ucose values 
are wi thin target range during dayt ime (0600 hours to midnight) at Week 16. The glucose target 
range is desfined as 70 to180mg/dL (3.9 to10.0 mmo l/L), both inclusive, ob tained from CGM . 
I8B-MC-ITRO(c)Clinical Protocol Page 86
LY900014Analyses will be performed for both the efficacy estimand and ITT estimand as described in 
Secti on [IP_ADDRESS] using the sa me graphical testing scheme.
The graphical testing scheme will be described in the SAP.  The study total alpha level (or 
study -wise ty pe I error) i s preset to be 5% for each estimand. The study  total  alpha level  will be 
used for the primary  objective in the init ial step. The alpha level will be allocated to other key  
endpo ints based on the weights in testing paths once the primary  endpoint i s successfully  
demonstrated. If [ADDRESS_563774] procedure continues unt il none of the remaining 
hypothe ses can be demonstrated with their preserved alphas or all hypotheses are demonstrated 
successful.   
An ANCOVA model as described in Section 10.3.1 will be used to analyze the 1 -hour and 
2-hour PPG excursions . However, if the percentage of the patients wi th missing MMTT data at 
baseline is higher than 15%, a constrained longitudinal data analysis model (Liu et al. 2009; Lu 
2010) will be used instead.  Analysis details will be documented in the SAP.
For continuous longitudinal secondary  endpoints, the MMRM model similar to that for the
primary  analysis will be used with HbA1c stratum (≤7.5%, >7.5%) added as a fixed effect.
Durati on and percent time in range , time in hypoglycemia and time in hyperglycemia derived 
from CGM data will also be analyzed using MMRM model with HbA1c stratum  (≤7.5%, >7.5%) 
as a fixed effect.   Conti nuous nonlo ngitudinal secondary endpoints will be analyzed using the 
ANCOVA model with treatm ent and strata as fixed effects and baseline as a covariate.   
Treatment comparisons for the propo rtion of  patients with HbA1c <7.0% and ≤6.5% will be 
analyzed using a lo ngitudinal logist ic regressio n with repeated m easurements conducted by  a 
generalized linear mixed model including independent variables of treatment, baseline HbA1c 
value, visit, baseline HbA1c by  [CONTACT_176260], and treatm ent-by-visit interaction.  Actual  and 
change from baseline in basal, bo lus, and total dose, as well as the bolus /total insulin dose ratio 
will be analyzed by [CONTACT_443232] 10.3.1 .
Leo Document ID = 162755db-eda4-4fa1-93bd-33cd456572f7
Approver: 
Approval Date & Time: 08-Oct-2019 14:38:18 GMT
Signature [CONTACT_32869]: Approved
Approver: 
Approval Date & Time: 08-Oct-2019 16:36:20 GMT
Signature [CONTACT_32869]: Approved
[COMPANY_003]
[COMPANY_003]